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Knowledge of genetic origins and associations of muco-obstructive lung diseases 
has made inhaled gene therapy an attractive alternative to the current standards of care 
that are limited to managing disease symptoms. However, despite over two decades of 
intensive research and development, gene therapy has yet to help patients with cystic 
fibrosis (CF) or any other muco-obstructive lung diseases. The slow progress is due in 
part to poor understanding of the biological barriers to inhaled gene therapy.  
In this dissertation, I first introduce the pathobiology of representative muco-
obstructive lung diseases and examine pitfalls of clinically investigated gene vectors of 
the past and of current options. I then review key components for successful execution of 
inhaled gene therapy, including gene delivery systems, physiological barriers and 
strategies to overcome them, and advances in preclinical models with which the most 
promising systems may be vetted for clinical trials. 
Secondly, I demonstrate that adeno-associated vectors (AAV), which are more 
commonly used gene vectors for clinical settings, differ in their ability to diffuse through 
the CF sputum barrier and mediate various levels of transduction depending on the 
surface chemistry. Specifically, I compared three AAV vectors in their ability to i) 
diffuse in CF sputum, ii) provide transgene expression in ALI culture of primary human 
CF bronchial epithelial cells, and iii) provide transgene expression in a mouse model of 
muco-obstructive lung diseases. 
Thirdly, I present the application of a synthetic biodegradable gene vector in ex 
vivo, in vitro, and in vivo models relevant to muco-obstructive diseases. This gene vector 
is composed of engineered poly(β-amino ester) polymers and nucleic acid that encodes 
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reporter or therapeutically relevant genes. I found that this gene vector, compared to 
conventional gene vector, is able to i) efficiently diffuse through CF sputum, ii) safely 
mediate higher magnitude of and widespread transgene expression in healthy and muco-
obstructive lung mouse model, and iii) apically transfer reporter gene to mucus-covered 
air-liquid interface (ALI) culture of primary human CF bronchial epithelial cells 
harvested from CF patient lungs with F508del homozygous mutation, the most common 
form of mutation in the CF patient population. 
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Muco-obstructive lung diseases consist of a group of respiratory disorders 
characterized by airway obstruction in the lungs of affected patients. All included 
diseases entail severe respiratory morbidity that often results in pulmonary failure and 
disease-associated mortality. Current treatments generally improve patient quality of life. 
However, these options do not tackle the root of the disease [1], and patients are required 
to follow cumbersome therapeutic regimens throughout their lifetime [2]. Gene therapy 
has emerged as a promising alternative approach as a result of the growing number of 
identified genetic causes and modifiers of muco-obstructive lung diseases. With advances 
in nucleic acid engineering, it is now conceivable to achieve gene transfer to specific cell 
types, including lung parenchymal cells [3-5], without affecting non-target cells [6]. In 
addition, persistent transgene expression during the life span of transfected cells can be 
achieved [7, 8].  
Therapeutic delivery via inhalation provides direct access to the target of gene 
therapy for muco-obstructive lung diseases, namely the cells lining the lung airways and 
airspace (i.e., alveoli), in a relatively non-invasive manner. The vast majority of 
preclinical and clinical studies of respiratory gene therapy have employed a pulmonary 
delivery strategy, including intratracheal/intranasal instillation and nebulization [9-11]. 
Nebulizers generate inhalable micron-sized liquid droplets that can carry hundreds of 
gene vectors per drop and reach virtually all areas of the lung [12]. However, despite 
encouraging safety and tolerability results, therapeutically effective inhaled gene therapy 
of muco-obstructive lung diseases has not yet been achieved. Lack of clinical success is 
due to the limited ability of gene delivery vectors to overcome difficult biological 
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barriers, which stems from a relatively poor understanding of the barriers. Improvement 
of this understanding may allow for more rational vector design strategies to tackle them. 
For example, accumulation of thickened airway mucus was recognized early on as a key 
pathological event of muco-obstructive lung diseases, but overcoming its barrier 
properties has typically not been addressed in the design of inhaled therapeutic delivery 
systems. In addition, most clinical trials involving airway gene therapy have been 
pursued as a result of positive outcomes observed in animal models that lack key features 
of human muco-obstructive lung diseases [13-16].  The disappointments in more than 25 
prior gene therapy clinical trials for cystic fibrosis (CF) alone have refocused research 
efforts on deepening knowledge of key issues that have prevented success of inhaled 
gene therapy.  
This dissertation is focused on these critical issues, including clinically-relevant 
gene delivery vectors, important biological barriers to successful gene transfer in the 
lungs, and rationally-designed approaches to overcome the barriers. This work is guided 
by the central hypotheses that i) pathological mucus barrier is problematic to inhaled 
gene vectors and ii) we can compare and identify promising viral or non-viral gene 
vectors by using appropriate tools and experiments. I first describe various muco-
obstructive lung diseases and their current state in the arena of academic research and the 
clinic, and suggest future directions for improved clinical outcomes. Then the following 
chapters introduce viral and non-viral strategies to treat muco-obstructive lung diseases. 
The respective gene vectors are validated for treatment of muco-obstructive lung diseases 
by using appropriate ex vivo, in vitro, and in vivo models that closely recapitulate the 





2.1.  Muco-obstructive lung diseases for inhaled gene therapy  
2.1.1. Cystic fibrosis (CF) 
 CF is the most common inherited genetic disorder in the US, and more than 
70,000 people are affected worldwide. CF is generally caused by one of many different 
possible mutations to a single gene that encodes cystic fibrosis transmembrane 
conductance regulator (CFTR).  Alteration of the CFTR ion channel protein causes 
abnormal ion transport between lung airway epithelial cells and the airway surface liquid 
(ASL), as well as similar ion transport defects in the gastrointestinal and genital tracts 
[17]. Pulmonary complications are the primary cause of CF-related morbidity and 
mortality [18]. Aberrant ion regulation in CF, including impaired chloride secretion and 
dysregulated sodium absorption, leads to dehydration of the ASL.  The result of 
dehydration is a thickened mucus gel in the airways that can impair mucociliary 
clearance (MCC) [19]. Altered biophysical properties of airway mucus, which impair 
mucus detachment, may also play a role in impaired MCC in CF [20]. Reduced rates of 
MCC cause mucus accumulation in the airways and provide a permissive environment 
for chronic bacterial infection and associated inflammation, which together can cause 
airway obstruction, fibrosis and, eventually, pulmonary failure [19, 21]. Airway 
dehydration, infection and inflammation are more pronounced in females with CF, which 
may be due to airway-related modulatory effects of estrogen [22]. As a result, females 
with CF have higher mortality compared to males with CF [22].  
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 Common inhalable treatments for CF, including recombinant human DNase 
(Pulmozyme®), hypertonic saline and antibiotics (TOBI®), alleviate disease symptoms, 
but do not address the underlying root of the problem, CFTR dysfunction. In 2012, the 
FDA approved the first drug that directly addresses CFTR dysfunction, Ivacaftor (VX-
770; Kalydeco®) [23]. Ivacaftor demonstrated significant improvements in lung function 
of CF patients [24, 25]. However, only patients with a specific class of mutations respond 
to Ivacaftor treatment, representing only a small subset of the patient population (~5%). 
Another drug, lumacaftor (VX-809), showed promising in vitro correction of the most 
prevalent CFTR mutation, F508del, which represents ~70% of CF patients [26]. This 
finding prompted its clinical evaluation, in combination with Ivacaftor [27], and the result 
was published in 2015 [28]. Although the trial demonstrated only modest improvement in 
pulmonary function compared to Ivacaftor in G551D patients [29], the combined 
formulation was recently approved by the FDA under the brand name of Orkambi®.  
 There are more than 1900 identified CFTR mutations, many of which are not 
expected to be responsive to currently available CFTR drugs [27]. Inhaled CFTR gene 
therapy, as a means to treat the underlying cause of the disease in the lungs, could benefit 
CF patients regardless of their specific CFTR mutation. However, over 25 clinical trials 
testing viral or non-viral gene vectors have failed to show clinical benefits, largely due to 
inefficient gene transfer to target cells [9, 10], including serous cells in the submucosal 
glands and ciliated airway epithelial cells [30]. Some viral CF gene therapy trials have 
been discontinued due to the generation of host immune response that renders subsequent 
treatments ineffective [10, 31]. It should be noted that lifetime repeated treatment is 
likely required for CF, as therapeutic effects will eventually fade away due to the 
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transient nature of episomal transgene expression [32] and/or the natural lifespan of 
transfected cells [7]. The UK CF Gene Therapy Consortium has recently completed the 
only CF gene therapy clinical trial that has been active in the past decade [33]. In this 
study, Alton et al. demonstrated, using a non-viral gene vector, a significant, yet modest, 
benefit compared to placebo control. They concluded that a more potent gene delivery 
vector is required to make gene therapy a viable option for treating CF [33].  
 Clinical trials for CF gene therapy have shown evidence of CFTR transgene 
expression based on measurements of CFTR mRNA and changes in nasal potential 
difference (NPD), but no significant improvement in lung function parameters has been 
reported [34, 35]. This suggests that the levels of gene transfer achieved in clinical trials 
have been insufficient to mediate functional cure in the CF airways. Nevertheless, 
optimism remains as several studies have suggested that a modest level of functional 
CFTR protein may be sufficient to improve lung function of CF patients. An early in 
vitro study suggested that only ~5% of airway epithelial cells need to produce functional 
CFTR proteins to restore chloride ion balance in the CF lung [36]. More recently, Pickles 
et al. used an in vitro model of human CF ciliated airway epithelium and found that at 
least 25% of cells may be required to express functional CFTR proteins in order to 
achieve mucus transport rates comparable to those in non-CF airways [37]. Interestingly, 
CF patients with certain mutations, which retain ~10% of normal CFTR expression per 
cell, are generally not afflicted by CF lung diseases [38]. Based on these observations, 
modest levels of CFTR protein expression throughout the airway epithelium could 
normalize pulmonary function in CF lungs.  
6 
 
 All CF gene therapy clinical trials to date have tested delivery of wild-type CFTR 
genes in order to provide functional proteins. However, approaches to rescue defective 
CFTR have been introduced in the literature, which involve miRNA [39], peptide nucleic 
acid [40], zinc-finger nuclease [41] and CRISPR/Cas9 [42] technologies. These studies 
demonstrated in vitro and/or in vivo restoration of the F508del CFTR function. Recently, 
the CF Modifier Consortium, which combines research efforts from groups in North 
America and France, completed a genome-wide association study to identify genetic loci 
relevant to CF pathophysiology [43]. In this study, samples from 6,365 CF patients with 
over 8 million genetic variants were analyzed and five genetic modifier loci associated 
with disease severity were discovered. This finding may provide additional genetic 
targets and enable individualized treatment of CF.  
 
2.1.2. α-1 antitrypsin deficiency  
α-1 antitrypsin deficiency (AATD) is another attractive target for gene therapy 
since it is also a monogenic disorder. AATD is caused by mutation in the gene encoding 
the serine protease inhibitor (α-1 antitrypsin; AAT). In normal conditions, AAT is 
synthesized predominantly in the liver, secreted directly into the bloodstream, and 
transported to the lungs where it protects alveolar interstitial elastin from degradation by 
neutrophil elastase [44]. However, reduced AAT secretion in AATD leads to 
protease/anti-protease imbalance and airway inflammation in the lungs. As a result, 
patients with AATD develop emphysema and chronic obstructive pulmonary disease 
(COPD; discussed in section 2.3), which is often triggered by environmental factors such 
as acute infection and cigarette smoking [9]. A small subset of AATD patients (<10%) 
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develops symptomatic liver disease. It is generally accepted that mutant AAT molecules 
polymerize and accumulate in the endoplasmic reticulum of hepatocytes, leading to the 
elevation of pro-inflammatory signaling [45].   
  Weekly intravenous infusion of AAT protein (i.e. augmentation therapy) is the 
only therapeutic option for AATD lung diseases that is currently approved by the FDA 
[44]. This protein-based augmentation therapy is well tolerated, effective in restoring 
AAT serum levels to the therapeutic threshold of 11 μM, and improves lung function [44, 
46]. However, the therapy is expensive and requires frequent dosing in the clinic. Thus, a 
gene therapy product that allows sustained production of AAT over a longer period of 
time may offer a significant advantage over the current therapy.  
There have been four clinical trials conducted for AATD gene therapy to date 
[47]. The first proof-of-concept clinical trial involved intranasal administration of non-
viral gene vectors carrying the AAT gene [48]. In this study, one-third of the level after 
AAT protein therapy was achieved, but the effect was transient. In subsequent trials, viral 
gene vectors were intramuscularly dosed to AATD patients, since the site or type of cells 
that produce AAT is irrelevant [47]. However, in a recent Phase II clinical trial, viral 
gene vectors administered via this route mediated AAT production at only 3-5% of the 
therapeutic target, necessitating an improved gene transfer strategy [49]. 
 Directly targeting the lungs via inhalation may provide a therapeutically-
beneficial level of AAT production at the site of action. Although there is no active 
clinical trial evaluating inhaled AATD gene therapy, inhalable AAT protein-based 
augmentation therapy is in progress in AATD patients with emphysema [46]. 
Encouragingly, an inhaled AATD gene therapy trial demonstrated superior anti-
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inflammatory effects in the lungs compared to intravenous protein therapy [48]. Gene 
therapy approaches for AATD liver diseases include the use of short hairpin RNA 
(shRNA) or miRNA for the knockdown of mutant AAT in hepatocytes; detailed 
information is available elsewhere [44, 46, 47]. 
 
2.1.3. Chronic obstructive pulmonary disease 
COPD is an incurable disease that is expected to be the third largest cause of 
death in the world by 2020 [50]. Cigarette smoking is generally accepted as the major 
cause of the disease, but exposure to environmental and/or work-related pollutants is also 
reported to be a significant factor [51, 52]. Abnormal inflammation and oxidative stress 
mediated by excessive inhalation of particulate matter and certain gases cause destruction 
of the extracellular matrix, leading to disease progression [51]. COPD is characterized by 
a progressive and irreversible airway limitation. This results from chronic bronchitis 
characterized by fibrosis, obstruction and remodeling of small airways [53]. Emphysema 
may also occur characterized by enlargement of airspace and destruction of lung 
parenchyma [53].  COPD patients with frequent exacerbations experience increased 
airway inflammation, dynamic lung hyperinflation, elevated bacterial colonization in the 
lower airways and increased susceptibility to viral infection of the airways, rendering the 
lungs the major target for treatment [54].  
 Smoking cessation is an important part of COPD treatment, however, many 
COPD patients continue to suffer from the disease due to irreversible functional and 
anatomical alterations [55]. Current treatments for COPD reduce symptoms only, and do 
not arrest or reverse deterioration in lung function and architecture that accompanies 
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moderate to severe disease. Available pharmacological treatments include 
bronchodilators, such as β-agonists and muscarinic antagonists, and inhaled 
corticosteroids, each of which offer short-term management of disease symptoms [56]. 
Other medications include mucolytic agents [57] and antibiotics [58], both recommended 
for patients undergoing acute exacerbations.  
COPD gene therapy research has been slow due to the highly variable disease 
etiology and lack of good animal models, each of which limit the pace of drug 
development [9]. While clinically-tested AATD gene therapies may also prove useful for 
treatment of COPD, mutations in the AAT gene are responsible for only ~1-3% of COPD 
cases [51]. Several genetic loci involved in protease/anti-protease, antioxidant, or anti-
inflammatory activities have been identified to exhibit polymorphisms associated with 
COPD [51]. However, preclinical evaluation of genetic intervention has not been 
extensively pursued. For example, pro-inflammatory cytokines like IL-18 and IL-1β have 
been implicated in COPD pathogenesis, but their potential role as therapeutic targets 
remains to be explored [59].  
Recent genetic, biochemical and histological evidence suggests altered 
transforming growth factor beta (TGF-β) signaling is associated with COPD development 
and progression [60-62]. TGF-β levels are elevated in the conducting airway (i.e., bronchi 
and bronchioles) and airspace compartments of patients with COPD [63-65]. In addition, 
Podowski et al. have shown that angiotensin receptor blocker antagonizes TGF-β 
signaling and, as a result, attenuates smoke-induced lung injury and rescues lung airway 
and airspace architecture in a mouse model of COPD [66]. Knocking down TGF-β 
signaling in the airways and alveolar sacs via gene silencing technologies may provide 
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similar therapeutic outcomes. Interestingly, cigarette smoking has been shown to reduce 
CFTR mRNA levels, CFTR protein levels and CFTR function, which contributes to 
mucus clearance defects in patients with COPD [67]. Thus, CFTR is another potential 
therapeutic target for COPD therapy.  
 
2.1.4. Asthma 
Allergic asthma is a global health problem caused by unregulated production of 
cytokines secreted by allergen-specific, type 2 helper T-cells (Th2 cells) [68]. Similar to 
COPD, both genetic predisposition and exposure to environmental irritants contribute to 
the development of asthma. Allergens presented to naïve T cells lead to expression of 
various cytokines, including IL-4, IL-5, IL-9 and IL-13, via the Th2 pathway, resulting in 
immunoglobulin E (IgE) production and mast cell recruitment [69]. Exposure of 
sensitized individuals to allergens induces release of histamine, leukotrienes and 
prostaglandins by mast cells in the lung airways, which promote vascular permeability, 
smooth muscle contraction and mucus production [69]. Subsequently, chemokines 
released by mast cells attract macrophages, eosinophils, Th2 cells and basophils to the 
airways, triggering airway inflammation, tissue damage, and allergen hypersensitivity 
[69]. 
Anti-inflammatory medication, specifically inhaled corticosteroids, is the most 
frequently prescribed therapy for asthma patients [70]. β2-adrenergic receptor agonists 
are also frequently used to dampen the inflammatory response by relaxing the smooth 
muscle [71]. While effective for most of patients, corticosteroids and β2-adrenergic 
receptor agonists are not always effective in patients with severe disease experiencing 
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exacerbation [72], and do not modify the course of the disease [73]. In addition, 
prolonged use of either medication elicits several side effects [74]. Gene therapy has 
emerged as a potential alternative or supplementary therapeutic approach that has been 
investigated in preclinical settings to date; gene silencing approaches are more common, 
but gene overexpression approaches are also being studied [69].  
Unlike CF and AATD, but similar to COPD, there are multiple genetic loci 
involved in asthma development and progression. This opens many opportunities for 
gene therapies aimed at a host of target cells, including lung epithelial cells, smooth 
muscle cells, and immune and inflammatory cells [9]. Using non-viral gene delivery 
platforms, a broad range of targeted proteins could be simultaneously activated with a 
single administration, which may be an advantage compared to interventions with small 
molecules, such as oligonucleotide (ONT)-based knockdown approaches [75]. Repeated 
dosing with ONT-based therapies failed to show sufficient therapeutic benefit over time 
[9, 74, 75]. In contrast, plasmid DNA-based strategies could provide long-term 
therapeutic effects with relatively infrequent administration.  
Evidence suggests that airway remodelling results in the progressive loss of lung 
function in asthmatics [76]. Thus, in addition to the therapies for attenuating airway 
inflammation, intervention of asthma-associated structural changes in the lung, including 
smooth muscle hypertrophy, wall thickening and collagen deposition, could reduce the 
rate of loss of lung function. Recently, da Silva et al. reported a proof-of-concept study 
where they evaluated effect of the gene encoding an active form of thymulin peptide in a 
mouse model of asthma [77]. Thymulin peptide has been shown to mediate anti-
inflammatory and anti-fibrotic effects in several disease models by modulating T cell 
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differentiation [78]. They found that a single intratracheal administration of a polymer-
based non-viral gene vector carrying thymulin plasmid DNA effectively prevented both 
the inflammatory and remodelling processes in the airways, thereby providing improved 
airway repair and lung mechanics in a mouse model of allergic asthma. Likewise, a viral 
gene vector carrying antisense against a cytokine that activates the Th2 pathway, IL-4, 
reduced airway remodelling in a rat model despite being systemically administered [79]. 
Overall, multiple targets may need to be tackled to cover the broad spectrum of the 
diseased population, but promising preclinical studies underscore that gene therapy is an 
attractive strategy for patients affected by severe asthma. 
 
2.2.  Gene delivery platforms 
2.2.1. Viral gene vectors 
Viruses have evolved to infect and transfer genetic payloads to host cells, which 
makes them attractive candidates for gene therapy applications. The recent approval of 
adeno-associated virus (AAV) type 1 as a vector for gene therapy in patients with 
lipoprotein lipase deficiency in Europe (Glybera™) [80] has provided renewed optimism 
in virus-mediated gene therapy. Numerous clinical trials using adenovirus (AdV) or AAV 
as gene vectors to treat muco-obstructive lung diseases have been completed, most of 
which have focused on CF due in part to its monogenic nature [81]. However, gene 
therapy clinical trials for CF using AdV and AAV2, dosed either intranasally or 
intratracheally, have failed to result in clinical benefits, and inefficient gene transfer to 
target cells has been cited as the primary reason [9, 10]. In addition, host immune 
responses to these vectors were found to limit gene expression after repeated 
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administration of the vectors [10, 31]. However, it should be noted both AdV and AAV2 
were well tolerated with limited adverse effects in these studies. Recent preclinical 
studies aim to more clearly define tissue tropism of the many available viral vectors and 
their alternative serotypes. In addition, sophisticated optimization of viral capsids and 
genomes (discussed in section 2.4.1) are further advancing the capabilities of next-
generation viral gene vectors. 
 
2.2.1.1. Adenovirus (AdV) 
AdV was the first viral gene vector tested in inhaled gene therapy clinical trials. 
AdV is a non-enveloped, icosahedral capsid virion with diameter ranging from 70 - 100 
nm. AdV has a genome capacity (36kb) that is much larger than typical viruses [82]. This 
allows full length CFTR, AATD, and other relatively large therapeutic nucleic acids to be 
packaged into AdV. AdV does not introduce its nucleic acid payload into the host 
genome, which results in transient transgene expression [83]. However, lack of DNA 
integration is a benefit in terms of safety since insertional mutagenesis has been observed 
with integrating viral vectors [84]. Importantly, the receptor that mediates AdV entry into 
airway epithelial cells, coxsakievirus-adenovirus receptor (CAR), resides on the 
basolateral side of the epithelium, which limits AdV’s potential efficacy in vivo for 
inhaled gene therapy [85, 86]. The innate immune responses, including generation of 
neutralizing antibodies against AdV, must also be addressed, as repeated administration 
of AdV will be required for most inhaled gene therapy applications [87, 88]. To begin to 
address this limitation, helper-dependent or “gutless” AdV (HD-AdV) have been 
produced wherein all viral DNA has been removed. Preclinical studies with HD-AdV 
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have shown promise [89, 90]. Toeitta et al. showed that HD-AdV administration resulted 
in reduced inflammatory response and improved airway transduction in mice compared 
to AdV [91]. Importantly, Croyle et al. showed that gene transduction in mouse lungs 
with HD-AdV was maintained after a second administration conducted 28 days after the 
initial dosing [92]. Airway transduction with HD-AdV has also been demonstrated in 
larger animals, including the ferret [93] and pig [94], further supporting its potential for 
inhaled gene therapy applications. 
  
2.2.1.2. Adeno-associated virus (AAV) 
Recent viral gene therapy trials have shifted to the use of AAV, as it overcomes 
many limitations of AdV. For example, AAV provides broad tissue tropism and more 
stable transgene expression with partial, site-specific integration into the host genome 
[10, 95, 96]. AAV is a non-enveloped, icosahedral, non-replicating capsid virus with a 
diameter of roughly 25 nm [97]. Infection of target cells with AAV is mediated by cell-
surface associated glycans, such as sialic acids and/or heparan sulfate proteoglycans 
depending on the AAV serotype [98-100]. As AAV vectors have shown broad tissue 
tropism, debate remains over the best-suited AAV serotypes for pulmonary applications 
[10]. AAV2 was the first discovered serotype [95], and is the only serotype tested in 
clinical trials of inhaled gene therapy to date [101-103]. Although efficient gene transfer 
was evident in the nares of humans, lung function in CF patients was not improved [101, 
102]. The disappointing outcomes with AAV2 mediated gene therapy In the lungs are 
likely partially due to the limited capacity of AAV2 to transduce airway epithelial cells 
via the apical membrane [10]. AAV2, similar to AdV, requires a receptor that is primarily 
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expressed on the basolateral side of the airway epithelium, specifically the heparan 
sulfate proteoglycan receptor, in order to introduce nucleic acid payloads into airway 
epithelial cells [99]. A Phase II clinical trial for CF utilizing AAV2 was dropped in 2005 
due to inadequate efficacy following repeated administration [103]. To this end, 
identification and/or engineering of AAV variants with enhanced infection capabilities 
via the apical membrane, lower immunogenicity, and desired tropism is likely required, 
especially given the therapy-inactivating immunogenicity generated by repeated 
administration of AAV2. In Phase I and II clinical trials for AATD, AAV1 and AAV2 
dosed intramuscularly did not reach their primary therapeutic endpoints, but rather 
showed transient and low production of wild-type AAT [47, 49]. Inhaled administration 
of next generation gene vectors, packaging AAT-encoding DNA, will allow production 
of AAT proteins at the target of therapy, which may provide a greater therapeutic benefit 
to patients afflicted with AATD. 
Investigations into alternative AAV serotypes, including AAV1, AAV5, and 
AAV6, have shown promising results, motivating their development for inhaled gene 
therapy. AAV5 mediated 50-fold greater gene transfer efficiency than AAV2 in air-liquid 
interface (ALI) culture of primary human airway epithelium (HAE) in vitro in one study 
[104]. The inherent tropism of AAV5 for airway epithelium results from its interaction 
with 2,3 N-linked or O-linked sialic acid receptors present on the apical surface of the 
airway epithelium [98]. Recently, a pseudotyped (hybrid) AAV gene vector, bearing 
AAV2 rep and AAV5 cap expression cassette (AAV2/5), achieved persistent gene 
transfer lasting up to 15 months in the airways and alveoli of mice following intratracheal 
administration (Figs. 2.1. A, B) [105]. They also found that re-administration of AAV2/5 
16 
 
14 months after the initial administration did not significantly reduce the gene transfer 
efficacy, presumably due to the long dosing interval [105]. As a result of this dosing 
interval, neutralizing antibody levels were reduced by more than 50% compared to peak 
levels after the first administration [105]. The process and rationale of pseudotyping viral 
gene vectors is discussed in detail in section 5.1. Similar to AAV5, AAV1 and AAV6 
require interactions with apically expressed receptors, 2,3 and/or 2,6 N-linked sialic 
acids [100], respectively, in order to transduce airway epithelial cells [100]. An in vitro 
study with ALI culture of primary HAE revealed that AAV1 exhibited orders of 
Figure 2.1. Viral vectors for inhaled gene therapy. (A, B) A recombinant AAV2/5 (AAV2 rep 
gene, AAV5 cap gene) delivered by intratracheal instillation demonstrates long-lasting gene 
expression (up to 15 months) in both conducting airways and alveoli of mice. (A) 
Immunohistological staining of β-galactosidase (β-gal) expression in alveoli and conducting 
airways 1 month post-administration. (B) Bioluminescence imaging of firefly luciferase 
expression in the lung and nose of mice at 1, 3, 6, 12, and 15 months post-administration. 
Reprinted from [105] with permission of Mary Ann Liebert, Inc. (C, D) A simian immuno-
deficiency virus pseudotyped with the respiratory pathogen Sendai virus (F/HN-SIV) 
demonstrates sustained transgene expression in the nose and lungs of mice after intranasal 
administration, lasting 22 months post-administration. (C) Fluorescent microscopy images of 
GFP expression mediated by F/HN-SIV in mouse lungs. (D) Bioluminescence imaging of 
firefly luciferase expression in the mouse lungs and noses at 2 and 22 months post-
administration. Reprinted from [131] with permission of the American Thoracic Society. 
Copyright © 2016 American Thoracic Society. 
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magnitude greater transduction efficiency than AAV2 and AAV5 when the vectors were 
administered to the apical side of the airway epithelium [106]. AAV1 also exhibited gene 
transfer efficacy following intratracheal administration in the airways of chimpanzees 
that was 20-fold higher compared to that achieved with AAV5, presumably due to a 
weaker T-cell response to AAV1 [107]. More recently, AAV6 was found to transduce 
mouse and dog airway epithelium in vivo [108], and HAE in vitro [109], to a level 
surpassing that achieved with AAV1, AAV2 and AAV5. In addition to the identification 
of AAV serotypes with lung tropism, modification of AAV to overcome other key 
barriers and therapy-inactivating immunogenicity is needed prior to human testing of 
next generation AAV for inhaled applications. 
A limitation of AAV is its relatively small packaging capacity for DNA payload 
(4.7 kb) [97]. All CF gene therapy trials to date have used the full-length, wild-type 
CFTR gene to produce functional CFTR protein. The relatively large size of CFTR 
cDNA (4.5 kb) has, as a result, greatly limited the selection of important regulatory 
elements in plasmid design, including promoter and enhancer components. [110]. Thus, 
clinical trials that have tested AAV-mediated CFTR gene transfer have utilized a weak 
promoter derived from inverted terminal repeat (ITR) [110]. ITR is a key element 
required for packaging therapeutic nucleic acid payloads into the AAV capsid  [111]. 
Several approaches have been developed seeking to circumvent this issue. Yan et al. 
utilized human bocavirus virus-1 (HBoV1) capsids to create a hybrid AAV virus with a 
larger packaging capacity (5.5 kb) [112]. In order to incorporate stronger promoters into 
AAV, shorter versions of therapeutic genes have also been engineered with a specific 
focus on CF gene therapy [113]. Specifically, truncated CFTR genes that rescue defective 
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CFTR, rather than synthesize the protein de novo, have been developed [114, 115]. 
Cebotaru et al. demonstrated that a truncated CFTR, Δ27-264 CFTR, delivered via 
AAV2/5, provided F508del CFTR restoration in vitro in polarized HAE with chloride 
currents approaching that of wild-type CFTR [115]. In an earlier report, they also showed 
that expression of another truncated CFTR, Δ264 CFTR, led to an increased level of 
wild-type CFTR production in the lungs of monkeys [116]. Another strategy to overcome 
the packaging size limitation inherent to AAV is to split the genome between two AAV 
vectors. This is achieved by either packaging overlapping genomes, which reconstruct the 
full length gene through homologous recombination after viral entry, or by evenly 
splitting the genome between two vector genomes that then combine after infection 
through trans-splicing via heterodimerization [117]. Using the former approach, 
intranasal administration of dual AAV6 vectors, carrying overlapping fragments of a 
reporter gene, resulted in production of the encoded protein in the mouse lung to a level 
comparable to what achieved by a single AAV6 carrying the intact gene [118]. This 
finding suggests that the additional recombination step may not significantly impact the 
efficacy of transgene expression.  
 
2.2.1.3. Retro- and lentivirus 
Retroviruses have also been investigated as viral vectors for use in inhaled gene therapy. 
Unlike AdV and AAV, retroviruses are capable of fully integrating nucleic acid payloads 
into the host genome via reverse transcription [119], thereby potentially providing longer 
and more stable transgene expression. However, insertion must be tightly controlled in 
order to avoid insertional mutagenesis that may result from random incorporation into 
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host chromosomal DNA [84]. In a prior clinical trial for X-linked severe combined 
immunodeficiency, 2 of 4 patients who were successfully treated with retroviral gene 
vectors carrying the c gene developed treatment-related leukemia [120]. Another 
limitation of retroviral vectors is their inability to infect non-dividing cells [121], which 
limits their use for inhaled gene therapy applications given the slow turnover rate of 
airway epithelium [7]. 
Other integrating viral gene vectors of interest are lentiviral gene vectors, 
including recombinant human (HIV) and feline (FIV) immunodeficiency viruses. In 
contrast to retrovirus, lentiviruses are capable of transfecting post-mitotic cells [122, 
123], including fully differentiated lung parenchymal cells. Lentiviral vectors have a 
packaging capacity large enough (8 kb) to accommodate full-length genes, such as CFTR 
[124]. However, lentiviruses have limited tissue tropism and, thus, capsid engineering is 
required to enable their use in gene therapy applications [124]. Initial preclinical studies 
have demonstrated efficient, persistent pseudotyped lentivirus-mediated gene expression 
in the lung [125-131]. For example, a recent study using pseudotyped lentivirus delivered 
intranasally showed gene expression in the lungs of mice that lasted up to 22 months after 
initial dosing without signs of toxicity or insertional mutagenesis (Figs. 2.1. C, D) [131]. 
The modifications used to introduce lung tropism to lentivirus-based gene vectors are 
discussed in detail in section 2.4.1. Further investigation into lentivirus-mediated lung 
gene therapy is warranted given the promising results thus far. However, whether 
lentiviruses can efficiently overcome physiological barriers unique to inhaled gene 




2.2.2. Non-viral gene vectors 
The majority of inhaled gene therapy clinical trials for muco-obstructive lung 
diseases to date have evaluated virus-based gene vectors. However, intrinsic limitations 
to their use for gene therapy over the lifetime of a patient, including therapy-inactivating 
immunogenicity and insufficient gene transfer in human airways to elicit clinical benefits, 
have spurred interests in development of synthetic systems [132, 133]. Synthetic systems, 
often referred to as non-viral vectors, are generally formed by multivalent electrostatic 
interactions between positively charged carrier materials and negatively charged nucleic 
acids. Unlike some viral vectors, non-viral vectors possess virtually unlimited nucleic 
acid packaging capacity [134], enabling the delivery of large, multiple and/or diverse 
nucleic acid payloads. Scale-up of non-viral vectors is relatively straight-forward 
compared to the complex procedures required for mass production of viral vectors [135]. 
Non-viral vectors can be altered to impart desired functionalities, such as the ability to 
penetrate through extracellular barriers [136], target specific cell types [137] and enhance 
intracellular delivery [138]. It is widely claimed that the primary disadvantage of non-
viral vectors is that they provide lower gene transfer efficacy compared to viral vectors 
[139]. However, few studies have been conducted where advanced non-viral vectors have 
been directly compared with viruses in vivo, where physiological barriers such as the 





2.2.2.1. Lipid-based gene vectors 
The earliest preclinical evaluation of inhaled non-viral vectors for gene therapy of the 
airways was conducted with lipid-based systems [140-142]. A seminal study reported by 
Stribling et al. reported results obtained from nebulized lipid-based gene vectors for 
inhaled gene therapy [142]. In their paper, aerosolization of a system based on N-[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA)/1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) safely mediated transgene expression in the 
majority of airway epithelial cells and alveolar lining cells at least for 21 days without 
signs of toxicity [142]. The promise provided by this and other early work [13, 143-147] 
enabled the prompt translation of the approach to clinical evaluation for inhaled gene 
therapy, with a specific focus on monogenic disorders, including CF and AATD. There 
have been 11 clinical trials with non-viral gene vectors for inhaled gene therapy of muco-
obstructive lung diseases to date, and all but one involved lipid-based formulations [148]. 
Based on promising observations in transgenic CF mouse models [13, 149], 
dimethylaminoethane-carbamoyl-cholesterol (DC-Chol)/DOPE was the first lipid-based 
system to be clinically evaluated [150]. These studies provided proof-of-concept for 
lipid-based inhaled gene transfer by showing partial NPD correction and a sign of CFTR 
transgene expression in several CF patients [11, 150]. However, similar to results with 
viral vectors tested in CF patients to date, the effects were modest and transient. Thus, the 
team tested whether repeated administration might provide more sustainable transgene 
expression [151]. Although clinical benefit was not achieved, the three doses of DC-
Chol/DOPE carrying wild-type CFTR were well-tolerated by CF patients without any 
evidence of immunologic side effects [151]. In addition, gene transfer efficacy was not 
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attenuated by repeated administration [151], unlike viral vectors [10, 31]. Other lipid-
based systems, including N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
chloride (DOTAP) [152] and p-ethyl-dimyristoylphosphatidyl choline cholesterol 
(EDMPC-Chol), have been tested in humans for inhaled gene therapy of CF. 
Unfortunately, the results were similar at best to the earlier single dose DC-Chol/DOPE 
studies [11, 150]. In the first and only clinical evaluation of the inhaled gene therapy of 
AATD using non-viral vectors, Brigham et al. compared nasally instilled DOTMA/DOPE 
carrying AAT-encoding plasmid DNA to the standard-of-care for AATD, weekly 
intravenous injection of AAT protein [48]. The concentration of AAT in nasal lavage 
fluids of patients who received the inhaled AAT gene therapy was about a third of the 
normal value that is achieved by AAT protein therapy. However, unlike the protein 
therapy, inhaled gene therapy reduced the levels of IL-8, a pro-inflammatory cytokine 
that is elevated in AATD patients [48].  
The Genzyme lipid 67 (GL67) is by far the most extensively studied lipid-based 
gene vector for inhaled gene therapy of muco-obstructive lung diseases. GL67 provided 
100-fold greater transgene expression compared to DC-Chol/DOPE [147], which was the 
first system tested clinically [150]. However, intranasal instillation of GL67, while 
achieving transgene expression on par with AdV, resulted in significant acute lung 
toxicity due to the need for high doses [147, 153]. Eastman et al. reported delivery of 
GL67 via aerosol significantly reduced the toxicity, but empirically determined that very 
high concentrations were required, which caused undesirable vector precipitation [142, 
154, 155]. To address this, they modified the system with a fraction of 
dioleoulphosphatidylethanolamine covalently coupled with 5 kDa polyethylene glycol 
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(PEG) [155], yielding a formulation named GL67A. Surface stabilization with PEG was 
later confirmed by in vitro studies showing that exposure to physiological concentrations 
of CF mucus components, including albumin, mucin, and linear DNA, did not undermine 
the gene transfer efficacy of GL67A [156]. Clinical studies with GL67A showed signs of 
CFTR transgene expression, but flu-like symptoms were observed in treated patients [11, 
157]. To potentially improve the safety profile, Hyde et al. investigated the effect of 
unmethylated CpG on GL67A-mediated in vivo gene transfer [158]. They demonstrated 
that while the presence of a single CpG in plasmid DNA was sufficient to elicit a pro-
inflammatory response, CpG-free plasmid DNA delivered via GL67A provided sustained 
transgene expression at least for 56 days without causing lung inflammation. In the 
meantime, GL67A was compared for in vivo gene transfer efficacy with other non-viral 
systems, including 25 kDa polyethylenimine (PEI)-based systems and clinically-tested 
PEGylated poly-L-lysine (PLL) (see section 3.2.1; [159])-based systems [14]. Among 
these, GL67A exhibited the highest levels of CFTR transgene expression in sheep lungs 
(Fig. 2.2. A, B) [14]. However, it should be noted that the doses were not matched in this 
study. Recently, a clinical trial testing repeated administration of GL67A carrying CpG-
free CFTR-encoding plasmid DNA was completed [160]. In this multi-dose trial, GL67A 
provided a significant, but moderate, improvement in the lung function of CF patients, 
suggesting that an improved gene delivery system is likely required to achieve 
therapeutically relevant outcomes [33]. Notably, monthly administration of the gene 
vectors to these patients was well tolerated over the course of the 12-month treatment 





Figure 2.2. Non-viral gene vectors for inhaled gene therapy. (A, B) Localization of gene 
expression in sheep lungs treated with GL67A carrying human CFTR (hCFTR)-expressing 
plasmid DNA. (A) Dual labeling of two hCFTR epitopes (G449, Texas red; MATG1061, FITC) 
of lung sections. Arrows indicate epithelial cells that are positive with both antibodies. (B) Dual 
labeling of cytokeratin and G449 (anti-cytokeratin antibody, red; G449, FITC). Reprinted from 
[14] with permission of Macmillan Publishers Ltd. (C, D) Localization of gene expression in the 
(C) medium (20x maginification) and (D) small airways (40x magnification) in the mouse lungs. 





 were fixed, sectioned, and immunohistochemically stained for the bacterial β-
galactosidase protein 2 days after intratracheal administration. Reprinted from [181] with 
permission of Macmillan Publishers Ltd. 
 
2.2.2.2.  Polymer-based gene vectors 
Cationic polymers have also been explored as a means to produce non-viral gene 
vectors for gene therapy. Among polymer-based systems, PEI is the most extensively 
studied in the preclinical setting. Linear and branched PEI with molecular weights over 
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20 kDa have been used most frequently due to their high charge density that enables 
efficient complexation of nucleic acid payloads [161] and strong buffering capacity that 
may help the gene vectors escape acidic vesicles inside the cell [162]. Multiple groups 
have investigated PEI complexes with nucleic acids for inhaled gene therapy [14, 163-
169]. Densmore et al. demonstrated that PEI-based gene vectors nebulized into mouse 
lungs produced a 10 – 100-fold greater pulmonary transgene expression compared to 
various lipid-based systems, including GL67/DOPE, DOTAP/DOPE and DC-
Chol/DOPE [164]. Importantly, repeated administration at a dose interval of 56 days of 
25 kDa branched PEI complexed with CpG-free plasmid DNA further boosted the 
transgene expression in the mouse lungs [163], suggesting that the effectiveness of 
repeated treatments was not limited by vector-induced immunogenicity. Nevertheless, 
clinical use of PEI alone as the condensing polymer in a non-viral vector system has been 
discouraged by some due to toxicity observed in animals caused by its high positive 
charge density and non-biodegradable nature [170, 171].  
Interestingly, Boeckle et al. demonstrated that removal of residual free PEI 
polymers (polymers in a formulation that are not complexed to DNA) by size exclusion 
chromatography resulted in significantly reduced toxicity and increased transgene 
expression of gene vectors based on 22 kDa linear PEI [172]. Likewise, removing free 
PEI by ultracentrifugation resulted in significantly greater pulmonary transgene 
expression with negligible toxicity in mouse and sheep lungs following aerosolized 
administration of 25 kDa branched PEI-based gene vectors [169]. These findings suggest 
that the toxicity of PEI-based systems is largely attributed to uncomplexed polymers, and 
that complete removal of free PEI from formulations will be a necessary step in future 
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clinical evaluations. Furthermore, since low molecular weight PEI is less toxic than high 
molecular weight PEI, several groups have developed PEI derivatives capable of 
degrading into smaller subunits in physiological conditions, such as in aqueous, acidic 
and/or reducing environments [173-176]. Of note, albeit not for inhaled gene therapy, 
PEI has been tested in clinical trials for other gene therapy applications [177, 178]. 
 Poly-L-lysine (PLL) is another well-studied studied cationic polymer for gene 
delivery applications.  While PLL alone has been associated with limited transfection 
efficiency and cytotoxicity [160, 179], a specific PLL-PEG based gene vector, namely 
CK30PEG10k, has been found safe when administered to human nares.  CK30PEG10k 
consists of a 30-mer PLL (30 lysine residues) covalently linked to 10 kDa PEG via a 
cysteine residue. CK30PEG10k has been shown to transfect airway epithelial cells in the 
lungs of mice (Figs. 2.2. C, D) [180], perhaps owing to its ability to interact with 
nucleolin on the surface of airway epithelial cells [181], without eliciting significant 
toxicity [182]. In addition, CK30PEG10K was shown to effectively complex plasmid DNA 
with sizes up to 20 kb [183] and to transfect post-mitotic cells [184]. The promise in the 
preclinical studies resulted in its evaluation in 12 CF patients who received CK30PEG10K 
complexed with human CFTR-encoding plasmid DNA administered intranasally [159]. A 
majority of treated patients exhibited partial to complete NPD correction without any 
noted side effects [159]. The level of gene transfer to the upper airway achieved by 
CK30PEG10k was comparable to the levels observed in trials of AAV2 at the highest titer 





Table 2.1. Gene vector platforms for muco-obstructive lung diseases 
Gene vector 
type 




Large nucleic acid packaging 
capacity (36 kb) compared to 
AAV [81] 
 
Non-integrating; no concerns 







expressed receptors for cell 
entry [84,85] 
 
Immune response limits 
efficacy upon re-
administration [9] 






Multiple serotypes  (e.g. AAV1, 
5 and 6) able to enter airway 
epithelial cells via apical cell 
surface receptors [94] 
 
More stable gene expression 
compared to AdV [94,95] 
Limited nucleic acid 
packaging capacity (4.7kb) 
[96] 
 
Immune response limits 
efficacy upon re-
administration [10] 
Clinical trials for CF [100-
102] and AATD [46,48] 
Lentivirus Long-term, stable gene 
expression [118]; lower dosing 
frequencies are achievable 
[130] 
 
Capable of transfecting post-
mitotic cells [121,122], unlike 
retrovirus [120] 
Safety concerns over 
insertional mutagenesis [119] 
 
Requires vector engineering 




Facile chemical modification 
[137] 
Minimal constraint in 
packaging capacity [151, 184] 
 
Large-scale production  [186] 
 
Variety of FDA-approved drug 
delivery formulations [187] 
 
Controlled release is achievable 
[139] 
Cytotoxicity [153, 173] 
     
No intrinsic tropism [139] 
 




(Lipid) Clinical trials for CF 
and AATD [148] 
 





2.3.  Physiological barriers to inhaled gene therapy  
2.3.1. Barriers in conducting airways  
2.3.1.1. Mucus gel layer 
Initial efforts to improve lung gene transfer focused primarily on efficiently 
overcoming cellular barriers to DNA delivery [188-190].  More recently, mucus covering 
the airway epithelium has been recognized as one of the greatest obstacles to overcome 
[191-195]. Airway mucus is primarily composed of a dense mesh of gel-forming mucin 
fibers, large macromolecules containing a high density of negatively charged glycans 
interspersed with periodic hydrophobic regions [196]. Thus, inhaled foreign materials, 
including gene vectors, are most often immobilized in the mucus blanket via multivalent 
adhesive interactions (e.g. electrostatic interactions, hydrophobic forces and hydrogen 
bonding) and/or steric obstruction. Gene vectors trapped in the mucus gel are cleared 
from the lung via mucociliary clearance (MCC) (3.6 mm/min [197]), which precludes 
them from efficiently reaching underlying target cells. In the lungs of people with muco-
obstructive lung diseases, including CF, COPD and asthma, mucus metaplasia and 
hypersecretion leads to mucus accumulation and impaired MCC, providing a permissible 
environment for chronic infection and inflammation [19, 21, 198-200]. Particularly in the 
CF airways, elevated levels of endogenous DNA and actin filaments released from 
necrotic neutrophils further contribute to the dense mesh structure of the airway 
secretions [191, 201].  
The average pore size of CF mucus is 140 ± 50 nm (range: 60 – 300 nm) [202], 
which is markedly smaller than the average pore size of human cervicovaginal mucus 
secretions (340 ± 70 nm) [203]. Recently, Fahy et al. reported that elevation of oxidative 
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stress in the lungs of CF patients increases disulfide cross-links between mucin fibers that 
increases mucus elasticity [204]. The increase in mucin crosslinking density also most 
likely causes the mucus mesh spacing to tighten further, thereby reinforcing airway 
mucus as a steric barrier. It is conceivable that other muco-obstructive lung diseases 
characterized by elevated oxidative stress, including COPD and asthma [205], may share 
this feature. The viscous drag on gene delivery vectors in the pores alone is not likely to 
pose a significant diffusion barrier, since the viscosity of the fluid in that fills these pores 
in normal airway mucus [206] or CF mucus [207] is only moderately higher than that of 
water. Of note, Coakley et al. have reported that estrogen reduces airway surface liquid 
height on the CF airway epithelium, which is restored by estrogen antagonist, tamoxifen 
[208]. Thus, mucus barrier properties may be more pronounced in females. Cigarette 
smoke coupled with progesterone exposure has also been reported to significantly elevate 
mucus cell metaplasia and accumulation of eosinophils in an asthma model, while 
progesterone alone does not [209]. MCC is likely impaired in both cases, which 
contributes to infection and inflammation in the airway, thereby increasing mucus barrier 
properties.  
Gene vectors that have been used in CF clinical trials recently have been shown to be 
incapable of efficiently penetrating CF mucus, including AdV [210], various serotypes of 
AAV including AAV1, 2 and 5 [210, 211], and CK30PEG10K [212, 213]. Likewise, non-
viral gene vectors based on the most widely explored cationic polymers, including PEI 
[214] and polyamidoamine (PAMAM) dendrimers [215], are unable to penetrate CF 
mucus, most likely due to the their positively charged surfaces that readily interact with 
negatively charged mucus constituents. It has also been shown that in vitro gene transfer 
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mediated by lipid- and polymer-based gene vectors and AdV was significantly reduced 
by CF mucus, underscoring its barrier property [216, 217]. Braeckmans et al. have 
demonstrated that negatively charged, hydrophobic polystyrene nanoparticles strongly 
adhere to the CF mucus mesh network (Fig. 3A) [207]. Thus, the limited success with 
gene delivery systems in clinical trials to date may be at least partly attributed to their 
inability to overcome the mucus barrier. Given the similar pathophysiological events in 
the airways of patients with other muco-obstructive lung diseases, the mucus blanket is 
likely to pose a similarly critical barrier to inhaled gene transfer. Indeed, diffusion of 
nanoparticles in COPD mucus has been shown to be hindered to a similar extent as in CF 
mucus [201]. 
 
Figure 2.3. Primary physiological barriers to inhaled gene therapy. (A) Mucus: A confocal image 
showing 89-nm polystyrene nanoparticles (PS NP) trapped via adhesive interactions within CF 
mucus. Reprinted from [207] with permission from Elsevier. (B) The periciliary layer (PCL): 
Adenovirus (AdV, blue arrows) is excluded from the PCL while adeno-associated virus (AAV, 
red arrows) penetrates into PCL and reaches underlying epithelium. Reprinted from [240] by 
permission from Macmillan Publishers Ltd. (C) Alveolar macrophages: an SEM image showing 
aerosolized 110 nm silver nanoparticles (Ag NP) accumulating in macrophages collected from 
broncheoalveolar lavage fluid  (BALF) after being administered to rats. Reprinted from [260] by 
permission from Oxford University Press. (D) Epithelial cell tight junctions: A confocal image 
(top: xy view, bottom: xz view) showing AdV restricted to the apical side of human airway 
epithelium due to the presence of tight junctions which prevents the access to receptors required 
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for cell entry. Reprinted from [272] with permission of the American Thoracic Society. Copyright 
© 2016 American Thoracic Society. 
Antibody trapping and/or neutralization can also contribute to inefficient gene transfer, 
specifically for viral gene vectors. Although antibodies diffuse in human mucus relatively 
unimpeded due to their small molecular size [218], the Fc region of antibodies make low 
affinity adhesive interactions with mucus [219]. As antibodies accumulate on the surface 
of pathogen, multivalent antibody interactions with the mucus mesh can trap the 
pathogen, thereby preventing their penetration to the underlying tissue. For example, 
Wang et al. recently reported that HSV serotype 1 (HSV-1) readily penetrated fresh 
neutralized human cervicovaginal mucus, but was trapped therein in presence of anti-
HSV-1 immunoglobulin G (IgG), which protected mice against vaginal infection [220]. 
A significant fraction of CF patients harbor active antibodies against AAV2 (32%) and 
AdV (55%) [221], which may further enhance adhesive entrapment in CF mucus and/or 
inactivate their capacity to transduce target cells. Further, neutralizing antibodies against 
AAV1, 2, 5, 6, 7, and 8 are often found in the airways of healthy people and people with 
CF [222, 223]. Neutralizing antibodies are also produced in response to administration of 
viral vectors, and their levels are elevated upon repeat dosing [10]. Thus, it is critical to 
determine if the presence of antibodies affects the mucus penetration rates of AAV in 
these patient populations.  
 In addition to its role as a barrier that prevents penetration of gene vectors, mucus 
may impair the colloidal stability of gene vectors due to the presence of various soluble 
macromolecules, proteins, lipids, surfactants and ions in the airways. For example, non-
viral gene vectors based on cationic polymers and lipids readily interact with negatively 
charged mucus constituents, resulting in large aggregates. Cationic gene vectors have 
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been shown to aggregate in presence of albumin (the most abundant protein in airway 
secretions [224]), DNA or mucin [156, 225, 226].  Viruses that possess positively 
charged surfaces, including HSV [227] and HIV [228], may share similar fates in the 
mucus gel. The aggregation of gene vectors may reduce gene transfer efficacy by further 
hindering diffusion in mucus, especially if the aggregates become larger than mucus 
mesh spacings [229]. Alton et al. showed that even mucus diluted 100-fold markedly 
reduced gene transfer by AdV and lipid-based gene vectors [230], which is partly 
attributed to the altered physicochemical properties of gene vectors mediated by soluble 
mucus constituents [195]. Negatively charged soluble materials in mucus may also 
compromise non-viral gene vectors by de-stabilizing complexation of DNA with cationic 
carrier materials. DNA molecules released from their vector are susceptible to 
degradation by endogenous nucleases present in the airways [231, 232].  
  
2.3.1.2.  Periciliary layer (PCL) 
Gene vectors trapped in the mucus gel layer of the airways are cleared by MCC or cough-
driven clearance [233, 234]. In contrast, gene vectors that rapidly penetrates through the 
gel layer and into the periciliary layer (PCL) may be retained significantly longer in the 
lung, as the PCL is believed to be nearly stationary [235-237]. Button et al. found that the 
PCL presents a significant steric barrier to vector penetration [238]. Using ALI culture of 
primary human bronchial epithelial cells, they showed that fluorescent dextran probes 
larger than 40 nm were excluded from the PCL, while smaller probes partitioned into the 
PCL and penetrated further toward the epithelium as size decreased [238]. These studies 
demonstrated that the PCL has a fine mesh structure, as opposed to being just a watery 
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layer as was previously suggested [239], and that nano-sized objects must pay a free 
energy price to penetrate the PCL [238]. Similar to the mucus gel layer, the PCL may 
also serve as an adhesive barrier since the meshwork is primarily composed of cell-
tethered mucins [238]. Kesimer et al. showed that the PCL excluded AdV (~100 nm in 
diameter), but not AAV (~30 nm in diameter; serotype not specified; Fig. 3B) [240]. In 
CF lungs, dehydration of the PCL mediated by dysregulation of epithelial sodium 
channels (ENaC) on the airway epithelium can cause an osmotically-driven collapse of 
the PCL [238, 241].  Collapse of the PCL likely further increases the barrier function to 
inhaled gene vectors by making the PCL mesh tighter. Despite being relatively less 
explored, airway dehydration appears to be a common concern for other muco-
obstructive lung diseases, including COPD [242] and asthma [243]. Overall, gene vectors 
capable of penetrating the mucus gel layer but not the PCL would most likely be cleared 
via MCC [214] or by macrophages [244].  
 
2.3.2. Barriers in airspace 
2.3.2.1.  Pulmonary surfactant 
Mucus is not present in the alveolar sacs of the lungs. However, inhaled gene vectors that 
make it to the alveoli must retain their stability and function in presence of surfactants 
that are abundant in the airspace. Pulmonary surfactant is a surface-active lipoprotein 
complex, synthesized by type II alveolar epithelial cells, that is composed of various 
phospholipids, cholesterols and surfactant proteins, including SP-A, B, C and D. To date, 
studies exploring the effect of pulmonary surfactants on lung gene transfer have primarily 
involved non-viral gene vectors [170, 245-251]. Gene transfer mediated by cationic lipid-
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based gene vectors was significantly reduced by pulmonary surfactants [248-251]. The 
stability of lipid-based gene vectors in the presence of various surfactants, including 
Alveofact (an extract from bovine lung lavage) and Exosurf (a synthetic surfactant) and 
individual components of pulmonary surfactant was investigated. Negatively charged 
phospholipids [248-251] and/or SP-B or C [250] were found to facilitate aggregation of, 
or DNA release from, lipid-based gene vectors, indicative of impaired colloidal stability 
or disruption of DNA-lipid complexation, respectively. While to lesser extents, Alveofact 
has been shown to reduce gene transfer efficacy of gene vectors formulated with cationic 
polymers, including PEI and PAMAM dendrimer [170, 248].  
Studies have also demonstrated surfactant-mediated aggregation of polymeric 
gene vectors [245, 246], however, DNA complexation was maintained with cationic 
polymer-based gene vectors, unlike lipid-based vectors, in the presence of pulmonary 
surfactants [248]. This carrier material-dependent effect is likely due to the difference in 
the nature of complexation by cationic lipids and polymers that influences vector stability 
in pulmonary surfactants. In addition to the disruption of complexation by negatively 
charged surfactants, hydrophobic lipid-surfactant interactions may render lipid-based 
vectors more susceptible to destabilization. Interestingly, incubation of polymeric gene 
vectors with pulmonary surfactants has been shown to enhance gene delivery efficiency 
in vitro due to improved cellular uptake and/or increased cell membrane permeability 
[246, 247]. Similarly, surfactants have been found to enhance AdV-mediated gene 
transfer to peripheral lung cells in vitro and in vivo [252, 253]; lipid recycling in 
pulmonary epithelial cells was suggested as a potential mechanism [253]. These findings 
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suggest that the effect of pulmonary surfactant on respiratory gene transfer may be 
multimodal and may vary depending on gene vector type. 
 
2.3.2.2.  Alveolar macrophages 
Alveolar macrophages are phagocytes residing in the airspace that play a critical role in 
homeostasis, host defense and tissue remodeling [254]. There are 12 -14 macrophages in 
each alveolus [255], which is increased in individuals who smoke regularly [256]. 
Alveolar macrophages engulf inhaled foreign substances directly or via an opsonin-
dependent mechanism. Particles in the size range of 250 nm to 3 m are readily 
phagocytosed by macrophages [257], with increasing phagocytic uptake with increase in 
the particle size within this range [258]. In contrast, particles smaller than 250 nm are 
taken up less efficiently by macrophages [257], including alveolar macrophages [259]. 
These findings suggest that alveolar macrophages may not pose a significant hurdle for 
gene vectors, since widely explored viral and non-viral gene vectors are generally smaller 
than 250 nm. However, aggregation of gene vectors in the presence of pulmonary 
surfactants may render them more susceptible to clearance by alveolar macrophages due 
to their increased size. For example, 20 and 110 nm silver nanoparticles delivered via 
aerosol to rat lungs were found as large aggregates that were engulfed by macrophages 
collected from broncheoalveolar lavage fluid (BALF; Fig. 3C) [260].  
Other properties of gene vectors, including surface charge, composition and 
particle geometry, play a critical role in phagocytosis [261]. In the case of polymeric 
nanoparticles, studies have shown that particles with hydrophobic surfaces are more 
readily internalized by macrophages than those with hydrophilic surfaces, while surface 
36 
 
charge did not appear to significantly alter the phagocytosis [261, 262]. Surfactant 
proteins such as SP-A and SP-D can opsonize inhaled gene vectors [263], which may 
facilitate opsonin-dependent phagocytosis by alveolar macrophages. Immunoglobulin 
(i.e. antibody) and complement are primary opsonins present in the lungs [264]. It has 
also been found that some viral vectors, including retrovirus and AdV, can be rapidly 
internalized by alveolar macrophages [265, 266]. It is possible that viral vectors are 
recognized by alveolar macrophages via Fc receptors on the surface of macrophages that 
bind to antibodies attached to the virus. Although it is a different organ, transient 
depletion of Kupffer cells, resident macrophages in the liver, enhanced AdV-mediated 
gene transfer in vivo [267]. In addition, it has been shown that complement cleavage 
fragment C3  and C3  opsonize non-viral gene vectors composed of cationic polymers 
or lipids [268], which may facilitate macrophage uptake via complement receptors.  
Vector-mediated inflammation through recruitment of neutrophils and 
macrophages [269] may further reduce gene transfer efficiency upon repeated 
administration. Alveolar macrophages may pose a more challenging barrier in the lungs 
of patients afflicted by diseases characterized by chronic infection and inflammation, 
such as CF [270] and COPD [271], where alveolar macrophages are activated. It has been 
shown that alveolar macrophages significantly reduce retrovirus-mediated gene transfer 
to human bronchial epithelial cells; the inhibitory effect is elevated by 




2.3.3. Cellular barriers  
Gene vectors that overcame the aforementioned extracellular barriers must then 
be taken up by target cells to introduce nucleic acid payloads to the intracellular gene 
expression machinery. Airway epithelial cells are a primary target for treatment of CF, 
and are of general importance to most muco-obstructive lung diseases. The epithelial 
surface of the airways poses an additional barrier to inhaled gene therapy that is due to 
low efficiency of endocytosis across the apical membrane [188] and tight junctions 
between cells that prevent access of gene vectors to the basolateral side [272] (Fig. 3D). 
This is a particularly formidable challenge for AdV since its receptor, CAR, is selectively 
localized on the basolateral membrane of airway epithelium [86]. Preclinical studies of 
lentivirus-mediated gene therapy in the lungs have also shown limited transduction 
through the apical membrane [273]. 
It has been reported that the barrier property of the airway epithelium is altered by 
muco-obstructive lung diseases, primarily due to structural perturbations of tight 
junctions [274-279]. In asthma, the barrier function of the airway epithelium is impaired 
through defective tight junction formation [274]. Likewise, cigarette smoke exposure, the 
major risk factor for COPD, disrupts tight junctions and increases epithelial permeability 
[275]. In contrast, it has been hypothesized that tight junction proliferation in CF results 
in increased epithelial resistance [276]. The transepithelial electrical resistance (TEER) is 
higher and the paracellular permeability is lower in CF airway epithelial cell cultures 
compared to cultures expressing wild-type CFTR [277]. However, pro-inflammatory 
cytokines [278] and bacterial toxins [279] reduce the permeability of tight junctions, 
suggesting that the barrier property of the airway epithelium may vary with disease state. 
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Tight junction proteins in the alveolar epithelium, including claudins [280], also limit 
access of inhaled gene vectors to the basolateral surface.  
Once taken up by target cells, gene vectors must overcome several intracellular 
barriers, including but not limited to acidic vesicles (i.e. endosomes and lysosomes), the 
molecularly crowded cytoplasm, and the nuclear envelope. These barriers are shared in 
numerous organs and tissues in addition to the lungs and, thus, are widely reviewed 
elsewhere [281, 282].   
 
2.4.  Strategies to overcome the barriers to inhaled gene therapy  
2.4.1. Modification of gene vectors 
Tuning gene vectors to overcome one or more important physiological barriers 
can enhance the efficacy of pulmonary gene therapy. Inhaled gene vectors deposited on 
conducting airways first encounter the luminal mucus gel layer that serves as a highly 
adhesive and steric barrier, as described in section 4.1.1. Thus, gene vectors must be 
small enough to traverse through the mesh spacing of airway mucus, while possessing 
particle surface resistant to muco-adhesion [133]. It has been reported that nanoparticles 
as large as 200 nm efficiently diffuse in human airway mucus freshly collected from 
individuals with [211] or without [206] muco-obstructive lung diseases, but only if 
particle surfaces are densely passivated with hydrophilic and neutrally charged PEG 
polymers. Of note, high PEG densities that yield brush conformations, as opposed to 
mushroom shapes, provides muco-inert particle surfaces [229, 283].  
Based on these findings, polymer-based gene vectors capable of efficiently 
penetrating human airway mucus, namely mucus-penetrating DNA nanoparticles (DNA-
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MPP), have been introduced [214, 215, 284]. Suk et al. demonstrated that DNA-MPP 
based on PEI and PLL, unlike the otherwise identical counterparts without dense surface 
PEG coatings, efficiently percolated through pathological human airway mucus ex vivo 
[214], followed by a similar observation with DNA-MPP formulated with biodegradable 
poly(−amino ester) (PBAE) (Figs. 4A, B) [284]. Likewise, the dense surface coatings 
with PEG corona may improve the penetration of inhaled gene vectors through another 
mucin-based meshwork found in PCL, if the particle diameters are small enough to fit 
through the PCL pores [240, 285]. The PEG surface coating may also minimize the 
particle aggregation in physiological environments [229], thereby providing another 
means of improving penetration through the steric barriers, including the mucus gel layer 
and PCL. Importantly, rapid ex vivo diffusion of DNA-MPP in airway mucus was 
translated to widespread distribution (Figs. 4C, D) and/or prolonged retention [214] in the 
mouse lungs, leading to approximately 25-fold greater in vivo pulmonary transgene 
expression compared to leading non-viral gene vectors without dense surface PEG 
coatings, including PEI- and CK30PEG10k –based systems [284].   
 Given that several viral vectors possess muco-adhesive surfaces [210, 211], their 
diffusion within the airway mucus is likely enhanced by a dense surface shielding with 
PEG, similar to the findings with non-viral gene vectors. The enhanced lung gene transfer 
efficacy of AdV by surface PEG conjugation has been previously reported [286, 287]; 
however, the benefit of PEG in these studies was experimentally determined to be either 
reduced immunogenicity or resistance to the neutralization by pre-existing antibody. 
Thus, the effect of PEG on the ability of viral vectors to overcome key physiological 
barriers to inhaled gene therapy is yet to be determined. It should be noted though that 
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interference of PEG with antibody binding will reduce Fc-mediated trapping of viral 
vectors in airway mucus. Other than the PEGylation approach, Schuster et al. have 
recently shown that AAV2 mutant possessing the capsid with reduced heparin binding 
exhibit significantly enhanced diffusion in human CF mucus compared to that of native 
AAV2 [211]. This is most likely attributed to the decrease in heparan sulfate-mediated 
adhesion of AAV2 to CF airway mucus rich in these proteoglycans [211].  
 Targeting cells of interest via specific ligands is certainly a viable approach to 
enhance gene transfer to the lung. Although the majority of studies involves cancer 
targeting due to numerous well-established pathways upregulated in cancers [288], 
several groups have reported feasibility of specifically targeting parenchymal cells in the 
lung, including airway and alveolar epithelial cells. Most of the relevant studies involve 
identifying targeting ligands for airway epithelial cells, reflecting the dominance of CF-
related research. Following the confirmation of urokinase plasminogen activator receptor 
(uPAR) expression on the apical surface of differentiated HAE, Drapkin et al., coupled a 
7-mer peptide derived from a respective ligand to the surface of AdV via PEG [289]. 
They found that the targeting AdV provide 10-fold greater gene transfer to airway 
epithelium in vitro compared to native and PEGylated AdV. Employing the phage 
display technology, Jost et al, identified a 7-mer peptide, THALWHT, that targets human 
epithelial cell lines [290]. Subsequently, an independent group genetically engineered 
AAV2 decorated with THALWHT and found that this mutant provided a significantly 
greater in vitro transgene expression both in undifferentiated and polarized (i.e. 
differentiated) HAE [291]. However, they were unable to identify any ligand harboring 
the sequence that targets polarized HAE and the mutant did not provide significantly 
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increased transgene expression in vivo, implying that the sequence may not be airway-
specific or may be species-dependent. Tagalakis et al. evaluated in vivo gene transfer 
efficacy of a lipid-based gene vector decorated with a peptide sequence previously 
identified to target intracellular adhesion molecule-1 (ICAM-1), a receptor for rhinovirus 
which causes the common cold [292]. They demonstrated that while their ICAM-1 
targeting formulation provided 99% of airways with evidence of bronchial epithelial cell 
transfection, 73% and 38% of airways showed epithelial expression with 22 kDa PEI and 
GL67, respectively, following intratracheal administration [292]. Similarly, lactoferrin 
[293] and lactose [294] have been shown to enhance the transgene expression of PEI- and 
PLL-based gene vectors, respectively, in the HAE. However, both studies were 
conducted using immortalized cells, and thus the validity of the approach should be 
confirmed with ALI culture of primary HAE. There are relatively few studies describing 
the targeted gene transfer to alveolar epithelial cells. In one study, 2-adrenoceptor 
agonist, clenbuterol (Clen), which is used as bronchodilator for COPD and asthma 
treatment, was incorporated onto the surface of PEI-based gene vectors [295]. The Clen-
decorated system provided 14- and 3-fold higher transfection efficiency compared to 






Figure 2.4. Modification of gene vectors to overcome physiological barriers. Representative 
trajectories of (A) conventional DNA nanoparticles (DNA-CP) and (B) mucus-penetrating DNA 
nanoparticles (DNA-MPP) based on biodegradable PBAE polymers in freshly expectorated CF 
mucus. Representative images of gene vector distribution in large airways following intratracheal 
administration of (C) DNA-CP and (D) DNA-MPP. Reprinted from [284] with permission from 
PNAS. Copyright © 2016 National Academy of Sciences, USA. (E, F) In vivo and (G, H) in vitro 
transduction of AAV6 and a mutant variant, AAV6.2, engineered with a single amino acid 
substitution in the heparin binding domain. Comparison of intratracheally administered (E) 
AAV6 and (F) AAV6.2 showing a stronger β-gal transgene expression in the mouse lung with 
AAV6.2. Comparison of (G) AAV6- and (H) AAV6.2–mediated GFP expression in ALI cultures 
of primary HAE. AAV6.2 treated cultures show stronger GFP expression as well as transduction 
of both ciliated and non-ciliated cells (H, inset). Reprinted from [109] by permission from 




In addition to incorporating specific ligands to the surface by covalent conjugation [289] 
or genetic engineering [291], other approaches have been widely explored to endow viral 
vectors with ability to be internalized by cells of interest. Directed evolution approaches 
have been used to generate libraries of alternative viral capsid types and screened for 
tropism based on transduction efficiency in vitro or in vivo [296-298]. Rational design, 
specifically capsid pseudotyping, has also been used where viral capsids are replaced by 
those from other virus types or serotypes known to efficiently infect cells in the lung to 
provide or enhance lung tropism. Given the promising preclinical and clinical results, 
AAV has been the most extensively engineered viral vector to date using both directed 
evolution and rational design approaches [296-298]. The rational design approach has 
also been used to engineer novel AdV and lentiviral vectors for inhaled gene delivery 
applications [299-301]. 
Libraries of mutant AAV variants have been generated using a variety of 
methods, including error-prone polymerase chain reaction, DNA shuffling or random 
insertion/deletion of peptide-encoding sequences [302]. Specifically for inhaled gene 
therapy applications, AAV mutant vector libraries can be screened in vitro using ALI 
cultures of HAE and/or in vivo with suitable animal models to determine which variants 
successfully mediate gene transfer. After multiple rounds of selection in ALI cultures of 
HAE, a mutant vector with shuffled cap genes from both AAV2 and AAV5 was 
identified with enhanced airway tropism and mediated 100 and 10-fold greater in vitro 
transgene expression as compared to native AAV2 and AAV5, respectively [303]. Using 
a similar approach, a mutant AAV vector containing shuffled cap genes from AAV1, 
AAV6, and AAV9 was identified by screening in polarized HAE and showed 3-fold 
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greater in vitro production of CFTR mRNA transcripts than native AAV6 and ~25% 
restoration of CFTR as compared to healthy controls [304]. By mutating single amino 
acids in the heparin binding domain of AAV6 capsid, Limberis et al. discovered a novel 
AAV6 mutant gene vector, AAV6.2, outperforming other native and mutant AAV at 
mediating gene transfer in mouse airways (Figs. 4E, F) and polarized HAE cultures (Figs. 
4G, H) [109]. 
 Using the pseudotyping approach, hybrid viral vectors have been engineered that 
contain envelope or capsid proteins from other viruses with alternative tissue tropisms to 
change gene transfer properties [296-298, 301]. AdV and AAV hybrid vectors have been 
generated with capsid proteins from alternative viral serotypes that use receptors 
expressed on the apical surface of airway epithelium for entry. For example, a 
pseudotyped AdV vector was engineered to incorporate AdV35 fibers into the AdV5 
capsid, redirecting tissue tropism towards airway epithelium with viral entry mediated by 
CD46 receptors expressed on the apical membrane [305]. A pseudotyped AAV vector 
containing an AAV2 genome packaged in AAV5 capsid proteins (i.e. AAV2/5) allowed 
for targeting of apically-expressed sialic acid receptors [116]. Using aerosolized AAV2/5, 
Fischer et al. demonstrated efficient gene transfer to the airways of monkeys to a level 
20-fold greater than what achieved in historical AAV2 studies [116].  
Incorporating components from the capsid of other respiratory viruses, such as 
bocavirus [112], baculovirus [9] and sendai virus (SeV) [9, 130, 306], is also a common 
strategy to introduce lung tropism. In addition to improving the packaging capacity, 
AAV2 pseudotyped with human bocavirus-1 (HBoV1) capsid demonstrated 5.6- and 70-
fold greater efficiency at transducing polarized HAE culture in vitro compared to native 
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AAV1 and AAV2, respectively [112]. They were able to transduce via the apical surface 
of primary HAE isolated from a F508del/F508del homozygous CF patient, resulting in 
~30% restoration of CFTR-mediated chloride currents [112]. Initial inhaled gene transfer 
studies with lentivirus focused on vectors pseudotyped with vesicular stomatitis virus G 
glycoprotein (VSV-G) [125-129]. However, this approach was generally developed to 
broaden the tropism of lentivirus rather than to specifically design a system for inhaled 
gene therapy applications [124]. It was later found for VSV-G-pseudotyped lentivirus 
that pre-treatment with compounds disrupting tight junction is required for gene transfer 
to the airway epithelium, suggesting that the transduction was achieved through the 
basolateral surface [125, 129]. To bypass the need for adjuvant treatments, hybrid 
lentiviral vectors were engineered by incorporating envelope proteins from SeV or 
baculovirus that have demonstrated tropism for the apical surface of airway epithelium 
[9]. Alton et al. were able to apically transduce in vitro in polarized primary CF HAE 
cultures and in vivo in CF mouse nasal epithelium using SeV-pseudotyped SIV [130]. 
The transgene expression in mouse nasal epithelium lasted up to 1 year after a single 
administration with no sign of immune response (Figs. 1C, D). This approach has 
significantly advanced the use of lentiviral vectors for inhaled gene therapy applications. 
 
2.4.2. Modulation of biological barriers 
Adjuvant agents that reduce airway and/or cellular barrier properties provide a 
relatively simple means to enhance the efficacy of inhaled gene therapy, potentially 
without the need of modifying gene vectors. However, it is crucial to ensure that any 
adjuvant approaches do not cause significant toxicity or disrupt normal lung function. 
This is of even greater concern for patients afflicted with muco-obstructive lung diseases 
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having impaired lung function. To our knowledge, specific strategies to reduce the barrier 
properties of the airspace are yet to be introduced, and as described in section 5.1, gene 
vector modification serves as the primary method to address this issue. 
The most widely explored approach in this category is the use of mucolytic agents 
that degrade primary macromolecular components of airway mucus. Two primary 
compounds of selection may be recombinant human DNase (rhDNase, dornase alfa, 
Pulmozyme®) and N-acetyl cysteine (NAC, Mucomyst®), which are currently or 
previously utilized in the clinic to help CF patients clearing accumulated mucus in their 
airways. NAC’s mode of action is to cleave disulfide intermolecular crosslinks between 
mucin fibers, which can significantly reduce the viscoelasticity of airway mucus [307]. 
As previously discussed, airway secretions in patients with muco-obstructive diseases can 
also carry high levels of DNA, further enhancing its barrier properties. Enzymatic 
degradation of DNA by rhDNase reduces entanglements within the mucus gel to further 




Figure 2.5. Modulating physiological barriers to inhaled gene therapy. (A, B) N-acetyl cysteine 
(NAC) treatment increases mucus mesh spacing, thereby facilitating gene vector penetration 
through airway mucus. Reprinted from [309] with permission from Nanomedicine as agreed by 
Future Medicine Ltd. (C, D) Reducing the osmotic pressure (OP) of mucus that can be achieved 
inhaled hypertonic saline rehydrates and restores the collapsed PCL. Reprinted from [238] with 
permission from AAAS. (E, F) Sodium caprate (C10) disrupts tight junctions in epithelial layer 
allowing gene vectors to access the basolateral compartment where specific receptors required for 
viral gene transduction are present. Reprinted from [272] with permission of the American 
Thoracic Society. Copyright © 2016 American Thoracic Society. The American Journal of 
Respiratory Cell and Molecular Biology is an official journal of the American Thoracic Society. 
In the context of inhaled gene therapy, NAC and rhDNase can enlarge the mesh 
spacings of airway mucus, reducing the physical obstruction of inhaled gene vectors. For 
example, NAC was shown to increase the average pore size of CF mucus from 145 ± 50 
nm to 230 ± 50 nm (Figs. 5A, B) [309]. It has been reported that pre-treatment with NAC 
leads to more rapid diffusion of leading gene vectors, including AAV1 [211] and 
CK30PEG10k –based system [213], through CF mucus. Accordingly, NAC significantly 
improved CK30PEG10k –mediated gene transfer in the lungs of a lipopolysaccharide-
induced mouse model of mucus hypersecretion [213]. Likewise, a NAC derivative was 
shown to enhance gene transfer efficacy of AdV [310] and non-viral gene vectors [216], 
including EDMPC-Chol and PEI-based systems, in the mouse lung in vivo and in an ex 
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vivo sheep trachea model, respectively. Suk et al. previously demonstrated that diffusion 
of nanoparticles as large as 200 nm in CF mucus was significantly improved by NAC, but 
the effect was greater when nanoparticles possessed muco-inert surface coatings [309]. 
This finding suggests that simultaneously modulating gene vectors and the mucus barrier 
may synergistically improve mucus penetration and thus the efficacy of inhaled gene 
therapy. In addition to clinically used agents, Yuan et al. showed methyl 6-thio-6-deoxy-
α-D-galactopyranoside reduced levels of reactive oxygen species in CF mucus and 
provided a greater reduction of disulfide crosslinks in CF mucus compared to NAC [204]. 
A novel alginate oligosaccharide compound, currently in a Phase IIb clinical trial for CF, 
was also shown to widen the pores within CF mucus by disrupting mucin-DNA 
interactions [311]. While safety must be confirmed, these newly developed mucolytic 
agents may also be useful as adjuvants for improving the penetration of gene vectors 
through the airway mucus barrier.  
Osmotic agents are another type of agent that may effectively reduce the barrier 
property of the airway mucus blanket. In particular, hypertonic saline is a clinically used 
osmotic agent to rehydrate the airways of CF patients and improve MCC [312]. Although 
it is yet to be tested, hypertonic saline may be used as an adjuvant to inhaled gene 
therapy, as it can potentially reduce the barrier property of airway mucus by diluting this 
gel layer. Improved MCC is likely achieved by the restoration of the collapsed PCL in the 
CF airways (Figs. 5C, D) [238], and thus inhaled hypertonic saline treatment may also 
render the PCL more permeable to inhaled gene vectors. Graeber et al. demonstrated that 
3% and 7% hypertonic saline administered via aerosol greatly reduced mucus 
accumulation in the airways of a ENaC-overexpressing transgenic mouse model of muco-
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obstructive lung diseases [313], presumably by increasing airway hydration and 
improving MCC. Mannitol (Bronchitol™) is another hypertonic osmotic agent that 
hydrates airways [314] and thus may also be useful as an adjuvant to inhaled gene 
therapy. The kinetics of hydration by inhaled hypertonic agents must be carefully 
evaluated in relevant preclinical or clinical settings in order to determine an adequate 
time interval between the pre-treatment and gene vector administration. Administration 
of gene vectors in hypotonic solution as a vehicle may also improve gene vector 
penetration through the mucus barrier via convective flow generated by the osmotic 
gradient established between the airway lumen and epithelial cells. Ensign et al. 
demonstrated that by using hypotonic solution as delivery vehicle, muco-inert (i.e. 
densely PEGylated) nanoparticles were able to rapidly penetrate the luminal mucus layer 
and reached the immediate surfaces of vaginal [315] and colorectal [316] epithelium in 
vivo. However, the effect and safety of this approach is yet to be established for delivery 
of inhaled therapeutics, including gene vectors. 
Use of hypotonic vehicle solution has shown potential of reducing the cellular 
barrier to inhaled gene therapy as well. Huang et al. demonstrated that hypotonic shock 
enhanced uptake of plasmid DNA by nasal epithelium in vivo via the regulatory volume 
decrease (RVD) mechanism [317]. Specifically, they showed that sodium- and sucrose-
based hypotonic vehicles provided enhanced transgene expression in the mouse nasal 
epithelium compared to isotonic vehicles with the greater effect observed with lower 
osmolality. Similarly, other studies have shown that fluorescently labeled compounds 
administered to airway epithelium in hypotonic vehicles were efficiently internalized by 
cells, whereas the same molecules in isotonic vehicle were not [318-320]. In addition to 
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the observations in conducting airways, Sawa et al. showed an enhanced transgene 
expression in the lung airspace of rats when plasmid DNA was intratracheally instilled in 
hypotonic, rather than isotonic, vehicle solution [321]. RVD occurs after cell swelling 
driven by hypotonic shock [322], stimulating the fusion of numerous intracellular 
vesicles with the plasma membrane to prevent cell lysis [323, 324]. The response 
involves release of intracellular ions and subsequent water loss by osmosis [325], leading 
to the internalization of excess apical and basolateral membrane to reform the lost 
intracellular vesicles. During this endocytic process, particulates, including inhaled gene 
vectors, in the vicinity of the apical membrane can be taken up by epithelial cells. The 
RVD effect has been shown to last up to 30 minutes [317, 319]. Potential safety concern 
resulting from hypotonic shock would need to be addressed before clinical 
implementation of this approach. 
As discussed earlier, several viral vectors possess natural tropism towards the basolateral 
surface of airway epithelium [85]. Thus, transient disruption of epithelial tight junctions 
may enhance transgene expression mediated by these vectors. Further, both viral and 
non-viral gene vectors may benefit from this approach due to the low rates of endocytosis 
across the apical membrane [188]. It has been shown that pre-treatment with fatty acid 
surfactants, including polidocanol (PDOC), sodium caprate (C10) and 
lysophosphatidylcholine (LPC), can increase paracellular permeability by transiently 
opening the epithelial tight junctions (Figs. 5E, F). Transduction by AdV was greatly 
enhanced in vivo in mouse nasal and airway epithelium pre-treated with PDOC [326] and 
C10 [327]. Likewise, pre-treatment with LPC has been shown to enhance VSV-G-
pseudotyped lentivirus transduction in vitro in polarized HAE culture [273] and in vivo in 
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marmoset [125] and ferret [129] airways. Calcium-chelating agents, such as ethylene 
glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), can also be used as 
adjuvants to reduce the intracellular concentration of calcium ions, thereby disrupting 
calcium-dependent formation of tight junction protein complexes [328]. Pre-treatment 
with EGTA has been shown to enhance efficacy of AdV and retrovirus gene transfer in 
vitro in polarized HAE cultures and in vivo in rabbit tracheal epithelium [329]. However, 
there have been concerns over the safety of this approach and potential adverse effects. 
To investigate this, Johnson et al. evaluated the safety of EGTA, C10 and sodium laurate 
(C12), in vitro in primary HAE cultures and in vivo in the lungs of mice where they found 
evidence of causing a minimal to mild inflammatory response, based on histopathological 
analysis [330]. However, this study revealed that EGTA increased cell counts and the 
levels of pro-inflammatory cytokines in BALF, while C10 and C12 altered airway 
responsiveness after methacholine stimulation in vivo in the lungs of mice [330]. LPC has 
been used most extensively as an adjuvant to VSV-G-pseudotyped lentivirus-mediated 
inhaled gene therapy to enhance gene transfer with minimal adverse effects reported 
[125, 129]. 
Table 2.2. Physiological barriers to inhaled gene therapy of muco-obstructive lung diseases and 
strategies to overcome them 
Regions of 
Lung 






Adhesive and/or steric 
trapping of inhaled gene 
vectors by mucus [202] and 
PCL [238] 
Engineer gene vectors with 
surface coatings to reduce 
adhesive interactions with 
mucus (e.g. PEG [214, 215, 
284], mutant AAV2 [211]) 
 
Sizes below characteristic 
mucus (≤150 nm) [202] and 
PCL (≤40 nm) [238] mesh pore 
size  
Mucus-altering agents (e.g. 
rhDNase [307, 308], NAC 
[309]) to increase mucus 
mesh pore size 
 
Osmotic agents (e.g. 
hypertonic saline [312], 
mannitol [314]) to increase 
mucus and/or PCL mesh 
pore size by hydration 
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Airspace De-stabilization of inhaled 
gene vectors by pulmonary 
surfactants [248-251] 
 
Uptake of inhaled gene 
vectors by alveolar 
macrophages [257-267] 
Engineer gene vectors with 
surface coatings (e.g. PEG 
[214, 215, 284]) to enhance 
particle stability and/or to 
reduce macrophage uptake 
None reported  
Cellular Low endocytic rate on 
apical surface [188] 
 
Restricted access to 
basolateral surface due to 
the presence of tight 
junctions [86, 273, 280] 
 
Introduce targeting ligands to 
enhance apical transfection 
[288-295] 
 
Engineer viral gene vectors to 
endow apical epithelial tropism 
(e.g. pseudotyping [296-298, 
301], directed evolution [302]) 
Tight-junction disrupting 
agents (e.g. C10 [327, 330], 
C12 [330], EGTA [328, 
330], LPC [125, 129, 273], 
PDOC [326]) to provide an 
access to the basolateral 
surface 
 
Hypotonic vehicles to 
enhance uptake by the RVD 
mechanism [317-324] 
 
2.5.  Preclinical models 
As discussed in previous sections, we have now learned through past successes 
and failures of preclinical and clinical studies the potential hurdles towards achieving 
therapeutically relevant inhaled gene therapy of obstructive lung diseases. Relevant 
preclinical models are needed in order to reliably evaluate newly developed strategies to 
better predict their performances in clinical trials. First, those models should replicate the 
physiological barriers found in the lungs of respective diseases to confirm whether the 
approaches of interest provide the benefits as designed. In addition, general pathology of 
respective human diseases should be reproduced in the animal models for assessing the 
pharmacodynamics (i.e. therapeutic gene transfer efficacy). In this section, we discuss the 





2.5.1 Cystic fibrosis 
Development of genetic animal models has greatly enhanced our understanding of 
CF lung pathophysiology. The CFTR-null (i.e. knockout) mouse was the first type of CF 
animal model established that results in a complete loss of functional CFTR [331-333]. 
This was followed by development of transgenic mouse models that produce low levels 
of CFTR [334, 335] and specific-mutant CFTR including but not limited to F508del 
[336], G551D [337] and G480C [338]. However, spontaneous generation of CF lung 
phenotype with mucus accumulation as well as chronic infection and inflammation is rare 
in knockout and transgenic mouse models with only one reported case [339]. This may in 
part be due to the lack of submucosal glands in the lower airways beyond the trachea of 
mouse lungs [340, 341]. Of note, submucosal glands are the primary source of the airway 
mucus secretion in the human lungs [200] and plays critical roles in innate immunity by 
secreting antimicrobials [342]. A recent study also found an alternative chloride channel 
is present in the mouse lung that can compensate for the lack of CFTR activity [93].  
It has been found that defective CFTR leads to hyperabsorption of sodium 
through dysregulated ENaC channels present on the apical surface of CF airway 
epithelium [343-345], and has been implicated as an initiating pathological event in the 
CF lung. Based on these findings, Livraghi-Butrico et al. have shown that transgenic 
mice overexpressing -subunit of ENaC spontaneously established CF-like lung disease, 
which resembles the pathological features of human CF lungs, including airway 
inflammation and dehydration as well as mucus obstruction [346-348]. Chronic lung 
infection, a hallmark of CF, has been established in normal mice and transgenic mouse 
model with specific CFTR mutation, including R117H, S489X, Y122X and F508del, 
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using Pseudomonas aeruginosa-laden agarose beads to prolong the bacterial residence 
time within the lung [349, 350]. Interestingly, inflammatory response to P. aeruginosa 
infection did not appear to depend on mutation type of the CF transgenic mouse models 
included in the study [349]. Mice intranasally challenged with endotoxin derived from P. 
aeruginosa have been shown to establish lung inflammation, mucus cell metaplasia and 
mucus hypersecretion [213], providing another relevant mouse model that mimics 
common features of the CF lung. 
 
Figure 2.6. Animal models of obstructive lung diseases. Airway obstruction develops in CF pig 
due to highly viscoelastic mucus (A; white arrow) in the airway where mucus cytology further 
revealed presence of neutrophils, macrophages, and bacteria (B). Reproduced from [351] with 
permission from AAAS.  Airspace in (C) healthy guinea pigs and (D) guinea pigs exposed to 
cigarette smoke (CS) for 6 months that show airway enlargement characteristic of emphysema in 
COPD. Reproduced from [374] with permission from APS. (E) Mucous cell hyperplasia, 
subepithelial fibrosis, and smooth muscle hypertrophy in ovalbumin (OVA)-induced allergic 




Larger genetic animal models have been developed using pig [351, 352], ferret 
[353-355] and rat [356] as background species, offering physiological features better 
reflecting the lungs of human CF patients [357-359]. It has been shown that pigs with 
mutated CFTR and/or CFTR knockout develop lung defects resembling those found in 
human CF lungs, including inflammation, impaired bacterial clearance, airway 
remodeling, and mucus hypersecretion (Figs. 6A, B) [351, 352]. A CFTR-null ferret 
model also shares features similar to humans with CF, showing altered airway chloride 
transport, mucus hypersecretion and propensity for lung infection [353-355]. These larger 
animal models are ideal for testing inhaled gene therapy, as they better recapitulate the 
physiological barriers and pathological events established in the human CF lungs. 
However, larger animal models are relatively costly, and accompany greater ethical 
challenges, and thus may be best suited for the later stages of preclinical development. A 
recent development of CFTR-knockout rats provides a model with more extensive 
development of submucosal glands in the trachea which may lend itself towards 
development of CF-like lung phenotype [356], thereby potentially serving as an 
alternative to aforementioned models.  
 
2.5.2 α-1 antitrypsin deficiency  
The most widely employed animal models for AATD to date were established in the 
1980’s [360-366]. These models are transgenic mice constitutively expressing a mutated 
version of an essential anti-protease, human AAT (hAAT), with a glutamate-to-lysine 
mutation at position 342 of the hAAT [367]. The mouse models harboring mutant hAAT 
exhibit low levels of hAAT in serum, caused by accumulation of the mutant protein in the 
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endoplasmic reticulum of hepatocytes, similar to what is found in AATD patients [363].  
However, none of these studies clearly demonstrated the development of emphysema, a 
key pathological characteristic in the lungs of human AATD patients. Thus, an advanced 
preclinical model that more closely mimics AATD lung phenotype is needed to reliably 
evaluate therapeutic outcomes of inhaled gene therapy. For example, emphysema can be 
established in mouse and rat lungs by disrupting the protease/anti-protease balance via an 
instillation of different types of proteases into the lungs, including, but not limited to, 
papain, human neutrophil elastase, porcine pancreatic elastase and galactosamine [368-
371]. It should also be noted that imbalance in protease activity is a common 
characteristic of a broader disease, COPD [372]. However, the lack of significant 
inflammation and airway changes [373] limit their use for studies that require general 
pathology of COPD, including chronic bronchitis. Other clinically relevant COPD animal 
models are discussed in section 6.3. 
 
2.5.3. Chronic Obstructive Pulmonary Disease 
There are a number of mouse-based COPD models, including cigarette-smoke (CS), 
protease-induced models, and genetic models. The most widely utilized models are 
generated by exposing rodents including mice and guinea pigs to CS [372, 374]. CS is 
exposed daily either only to the nose or whole body [375] for an extended period of time, 
usually weeks to months, to establish COPD-like pathology, including elevated oxidative 
stress [376], chronic inflammation [377], small airway remodeling and/or emphysema 
(i.e. enlargement of the airspace compartment; Figs. 6C, D) [378].  The nose-only 
administration allows for more direct control of amount of CS exposure compared to 
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whole body exposure, but mandates prolonged restraint of the animals, which may cause 
stress. Using either administration modality, the effects of CS exposure can be closely 
monitored based on levels of CS exposure markers such as carbon monoxide-hemoglobin 
complexes (i.e. carboxyhemoglobin) and nicotine metabolites (e.g. cotinine) present in 
serum [375]. 
 Using nose-only CS exposure, Beckett et al. recently demonstrated that an 8-
week exposure of CS to mice twice per day and 5 times a week resulted in COPD-like 
pathology, including airway inflammation, emphysema and impaired lung function 
(determined by forced oscillation and forced maneuver techniques), which was not 
resolved during the following 4 weeks of CS cessation [379]. The lungs of this model 
also became susceptible to acute bacterial infection, as evidenced by decreased clearance 
of Streptococcus pneumoniae and influenza virus by 2-fold in comparison with wild-type 
mice [379], presumably replicating pulmonary exacerbation often observed with COPD 
patients [380]. However, mucus accumulation and airway obstruction are not established 
in this model, despite the presence of goblet cell metaplasia and airway remodeling [379]. 
As a result, this model may be limited in evaluating therapeutic intervention of the 
chronic bronchitis phenotype.  
CS models have been also generated using other larger species such as guinea 
pigs [381, 382].  Guinea pig-based CS models have been favored by several groups due 
to its unique advantages, including relatively close resemblance to human lung 
physiology and anatomy [383-385] as well as lung alveolarization at birth which may be 
beneficial for pre- and neonatal studies [386]. In addition, hallmark features of COPD 
including inflammation [387, 388], goblet cell metaplasia [389, 390], small airway 
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remodeling [391, 392], airway obstruction [393] and emphysema [394], have been 
successfully demonstrated in guinea pigs. COPD has been extensively studied over the 
years with the use of various CS-induced animal models reported by numerous groups, 
but development of a standard CS exposure protocol seems necessary as it is currently 
difficult to directly compare studies by different groups.   
The COPD animal models based on genetic variations include natural mutant, 
transgenic and knockout models. Some of these models may offer the advantage of 
consistency, however they do not always reflect the COPD pathogenesis specific to the 
lungs and may adversely affect other organs [373]. Interestingly, some naturally 
occurring mutant strains of C57BL/6 mice, such as tight skin and pallid mouse models, 
are known to have abnormally large airspace, lower serum level of AAT and impaired 
alveolar septa [369, 395]. Tight skin mouse model is characterized by a mutation in the 
fibrillin-1 gene, which affects formation of elastic fibers, leading to abnormal airspace 
development and progressive alveolar enlargement with age [396, 397]. Pallid mouse 
model is known to have lower level of AAT in serum and gradually develops mild 
emphysema late in life [369]. The pallid mouse model may also be utilized for AATD 
studies [398]. Transgenic and knockout models may be more useful for studying a 
particular pathway of the COPD pathogenesis, as exact roles of specific genes can be 
elucidated in these models.  
 
2.5.4 Asthma  
The ovalbumin (OVA)-challenged mouse model is by far the most widely utilized 
preclinical model for allergic asthma, exhibiting the characteristic Th2-type immune 
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response [399]. The models are generally established by intraperitoneal sensitization with 
OVA, followed by repeated intratracheal OVA challenges, but exact dosing schedule 
varies among individual studies [400]. The model reliably recapitulates asthma-like 
pathophysiology, including recruitment of eosinophils, elevated levels of OVA-specific 
IgE and Th2 cytokines, mucus accumulation by mucous and goblet cell hyperplasia, 
airway hyperresponsiveness and airway remodeling (Fig. 6E) [401, 402]. Although the 
OVA mouse model is the most widely used, there are questions regarding its clinical 
relevance as OVA is not a naturally occurring allergen. Hence, it may not properly mimic 
how asthmatic patients become sensitized to allergens [403]. Numerous groups using this 
model have reported that chronic asthmatic symptoms do not exacerbate over time; the 
symptoms are actually ameliorated by natural development of tolerance and/or 
termination of OVA challenge [404, 405]. More recently, the development of tolerance to 
repeated challenges has been addressed by optimizing amount and frequency of OVA 
administration [77, 400]. Although not as frequently used, rats and guinea pigs are also 
utilized as background species of OVA models. Rat models share similar immunological 
cascade as the mouse model when sensitized with OVA and may perhaps be used as an 
alternative [406]. Guinea pigs, while closely resembling the human lung anatomy and 
physiology, have been reported that IgG is the primary antibody produced post-
sensitization and the baseline level of eosinophils is high, which may somewhat limit 
their use [406, 407].  
Mouse models have been also developed using naturally occurring allergens such 
as house dust mite (HDM) [408].  Many groups favor HDM models over OVA models as 
it yields pathophysiology similar to that exhibited by the more widely-studied OVA-
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sensitized model, while also having greater environmental/clinical relevance [409].  For 
example, Johnson et al. administered HDM intranasally for 5 days per week for up to 7 
weeks and observed eosinophilic inflammation, elevated levels of Th2 cytokines, as well 
as airway hyperresponsiveness and remodeling [401, 409]. Additionally, in contrast to 
OVA-challenged animal models, re-exposure of HDM to mice resulted in sustained 
inflammatory response, including elevated eosinophil and Th2 effector cell counts, 
suggesting that tolerance to HDM did not develop [409]. However, after cessation of 
HDM exposure, airway inflammatory response fully recovered, while alterations in 
airway remodeling and hyperreactivity persisted [409]. HDM consists of a mixture of 
allergen subtypes including Der p I and Der p II and other biomolecules such as 
endotoxins, proteases, proteins and peptides, making it difficult to identify the 
component(s) responsible for specific allergic responses [401, 410, 411]. Moreover, 
many commercially available HDM extracts are different in composition and proteolytic 
activities [412], and thus direct comparison of various HDM studies can be difficult.  
Use of transgenic mice overexpressing GATA3 transcription factor may be 
considered. GATA3 is known to play significant roles in Th2 cell differentiation and 
activation by controlling Th2-driven cytokine production [413]. Several groups 
demonstrated that mice with GATA3 overexpression, in comparison to its normal 
counterparts, showed upregulation of Th2 cytokines, airway remodeling, airway smooth 
muscle hyperplasia, eosinophilic inflammation and subepithelial fibrosis, upon 
sensitization and challenge with allergens [414-417]. Overexpression of GATA3 alone 
induces production of Th2 cytokines and leads to lung inflammation and mucus 
hypersecretion, but not to the extent exhibited after allergen challenge [413].  
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Sensitization of GATA3-overexpressing transgenic mice with even relatively low amount 
of OVA or HDM cause further increases in airway inflammation, while no significant 
inflammation was observed in wild-type C57BL/6 mice [413]. In another study, Ano et 
al. sensitized and subsequently challenged GATA3-overexpressing transgenic mice with 
OVA and were able to observe enhanced airway inflammation and goblet cell hyperplasia 
[414]. A Phase IIa trial of an inhaled DNAzyme targeting GATA3 mRNA have been 
recently initiated for Th2-driven asthma [418], underscoring the relevance of these 
transgenic mouse models.  
Larger animal models based on non-human primates, ponies, and Basenji 
greyhounds have been developed since they develop natural allergies as well as persistent 
respiratory allergic responses; however, they have not been widely explored primarily 
due to cost issues [419]. 
 
2.6.  Human Tissue Culture Models 
Therapeutic efficacy and safety of novel delivery strategies must be ultimately 
demonstrated in preclinical animal models prior to their clinical evaluation. However, 
recent studies have shown species-specific differences in tropism of AAV by comparing 
transduction in vitro in ALI cultures of human lung epithelium to those of mouse [420], 
monkey [359], ferret [359] and pig [421] lung epithelium. These findings underscore the 
importance of confirming the efficacy in relevant human cell-based models as compared 
to preclinical models. Studies in human tissue culture models are also beneficial for high-
throughput screening of gene vector candidates and further optimization of vector design. 
Human lung epithelial cells grown in ALI cultures have the ability to differentiate into 
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polarized epithelial layers, developing key physiological barriers including tight junctions 
between neighboring cells and mucus secreted from the apical surface within ~4 weeks 
[422, 423]. Ussing chamber experiments can be conducted to confirm the presence of 
intact tight junctions determined by the measured TEER [422, 423] and also to assess 
CFTR correction via quantifying the chloride conductance [26, 115, 277].  
ALI cultures have been generated from lung epithelial-derived cell lines, 
including Calu-3, CFBE, NuFi-1, and CuFi-1 (for complete list of available cell lines, see 
[424]). However, concerns arise around the use of ALI cultures established with a single 
cell type, as there are several different cells present in the lung (i.e. ciliated epithelial 
cells, goblet cells, etc.) [424-426]. Mucus production and PCL development may also 
vary greatly depending on the cell lines used [424-426]. Thus, the properties of relevant 
delivery barriers encountered by gene vectors may not fully recapitulate their 
characteristics in the human lung. Primary ALI cultures are an attractive alternative as 
they are established with airway cells directly collected from human lung explants and 
thus retain many features of the physiological human lung epithelium [238, 241, 427-
430]. Another benefit is that epithelial cells can be harvested directly from specific 
patients of interest for screening gene delivery strategies, potentially enabling 
personalized medicine. Shortcomings of primary ALI cultures include limited availability 
of fresh explants, short cell lifespan, and variability among patient donors. It should be 
also noted that submucosal glands, an important target tissue in obstructive lung diseases, 
are not present in ALI cultures regardless of the source of constituting cells.  
Recent developments in nasal brushing-derived primary lung epithelial ALI 
cultures could provide a more readily accessible tissue source [431]. However, there are 
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concerns over its use as a surrogate tissue source as studies have shown marked 
differences in genomic profiles of primary human nasal and bronchial epithelial cells 
[432, 433]. Primary human organoids differentiated from patient-derived stem cells are 
also an attractive in vitro model for high-throughput screening [434]. Specifically for CF, 
the organoid’s degree of swelling in response to the treatment with a well-documented 
CFTR activator, forskolin, was found to correlate with CFTR function, providing a 
means to assess CFTR activity and/or correction [435]. The organoid systems remain 
viable after long periods of storage in liquid nitrogen and could be passaged up to 40 
times, beneficial for long-term studies. More recently, this approach was expanded to 
human lung organoid systems consisting of proximal lung epithelium surrounded by 
mesenchymal smooth muscle tissue and have been shown to generate airway-like 
features with both club and ciliated cell development [436]. However, the barrier 
properties of organoid systems have not been thoroughly characterized and may differ 
from those observed in the human lung.  
 
2.7.  Conclusion  
Over two decades of preclinical and clinical evaluations of inhaled gene therapy 
have provided valuable lessons building towards the ultimate goal of developing curative 
treatments for patients with obstructive lung diseases. We have now established better 
understanding of disease pathology, genetic targets and physiological barriers. The 
accumulated knowledge has driven the development of advanced gene delivery systems, 
nucleic acid engineering tools and human disease-like preclinical models by scientists, 
engineers and clinicians in various settings. A recently completed clinical trial of inhaled 
64 
 
CF gene therapy has left some questions to be addressed, but has certainly rejuvenated 
the field with more clinical evaluations anticipated in the near future. Through this 
review, we hope to provide a comprehensive overview of the knowledge gained and 
encourage collaborative efforts for realizing therapeutically effective gene therapy of 
obstructive lung diseases. We began our review by overviewing the types of obstructive 
lung diseases and potential genetic targets for respective diseases. We then highlighted 
gene delivery systems, primarily those tested in clinical trials of inhaled gene therapy, 
followed by challenging physiological barriers that have hampered translation into the 
clinic. We next introduced strategies to overcome those hurdles and preclinical disease 
models resembling the pathological lung environments of diseased human patients. 
Future preclinical studies of the next-generation of gene vectors in animal models that 
present all these critical features will help better predict therapeutic outcomes and thus 




3. An adeno-associated viral vector capable of penetrating the mucus barrier to 
inhaled gene therapy 
 
3.1.  Introduction 
Past clinical trials testing viral gene vectors, including adenovirus (AdV) and 
adeno-associated virus (AAV) serotype 2, for inhaled gene therapy have failed to provide 
clinically significant benefits. These disappointing outcomes have been attributed to 
inefficient gene transfer to airway epithelium and generation of therapy-inactivating host 
immune responses [437]. Accordingly, recent advances in viral vector engineering have 
focused on enhancing the transduction of airway epithelium [107, 109, 112, 438-443] and 
reducing immunogenicity [444, 445]. While underappreciated in early clinical studies, 
airway mucus has been recently recognized as another critical biological barrier to 
inhaled therapeutics [133, 446-453]. The airway epithelium is protected by a secreted 
mucus gel layer that traps most inhaled foreign materials, including gene vectors, and 
facilitates their removal from the airways via mucus clearance mechanisms [446, 454, 
455]. In previous studies, we found that many clinically tested and commonly used viral 
vectors, including AdV, AAV1, AAV2 and AAV5, bind adhesively to human airway 
mucus [456, 457], impeding access to the epithelium that is required for successful 
transduction. 
Recent studies comparing AAV serotypes for inhaled application revealed that 
AAV6 provided superior gene transfer efficacy in vitro and in vivo to other serotypes 
[109, 458-460]. However, the underlying mechanisms are not fully understood with one 
report suggesting a potential role of its ability to escape the proteasome degradation 
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pathway [458]. In addition, many prior studies have been conducted using in vitro and in 
vivo models that lack the lung pathophysiology similar to that of patients with muco-
obstructive lung diseases, such as cystic fibrosis (CF), chronic obstructive pulmonary 
disease (COPD) and asthma. To this end, we sought to evaluate the performance of 
AAV6 in the lung using physiologically relevant experimental conditions, including 
human CF sputum, a mucus-covered air-liquid interface (ALI) culture of human CF 
airway epithelium, and an advanced transgenic mouse model closely mimicking the lung 
environment found in muco-obstructive lung diseases. Using multiple particle tracking 
(MPT), we first investigated whether AAV6 was capable of avoiding entrapment within 
the mucus meshwork of CF sputum, unlike previously tested AAV serotypes [456, 457]. 
We then determined the impact of the airway mucus barrier on the ability of AAV6 to 
mediate transgene expression in airway epithelium in vitro and in vivo, and compared 
AAV6 to AAV1, a serotype shown to outperform the clinically tested AAV2 [106, 461] 
but unable to efficiently penetrate human CF sputum [457].  
 
3.2.  Materials and Methods 
3.2.1. Production of recombinant AAV gene vectors and fluorescent labeling 
Recombinant AAV1, AAV6 and an AAV6 mutant, AAV6-K531E, vectors were 
packaged with either self-complementary enhanced green fluorescent protein (scAAV-
EGFP) or single-stranded firefly luciferase-yellow fluorescent protein fusion (ssAAV-
Fluc-YFP) gene as described previously [462, 463]. Both reporter transgenes are 
expressed under the control of the ubiquitous chicken β-actin promoter (CBA).  To 
engineer AAV6-K531E, a two-step PCR with reading-proof Turbo Pfu Polymerase 
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(Stratagene) was used on plasmid pACGr2/c6 to introduce a single mutation;[464, 465] 
primers were designed to make a change in an amino acid coding triplet from lysine (K; 
codon: AAG) to glutamic acid (E; codon: GAG) at 531 position of AAV capsid. The 
titers of DNase I-resistant vector particles were determined by qPCR using the primer-
pair specific for the CBA promoter, F-5’-TCCCATAGTAACGCCAATAGG-3’ and R-
5’-CTTGGCATATGATACACTTGATG-3’, and SYBR GreenER PCR Master Mix 
(Invitrogen). Of note, two separate batches of AAV vectors were constructed and used 
for in vitro and in vivo transduction studies to ensure reproducibility. For visualization 
and tracking of individual viruses, AAV was labeled with the amine-reactive fluorescent 
dye, Alexa Fluor 647 carboxylic acid succinimidyl ester (AF647; Life Technologies), as 
previously described [457]. AF647-labeled AAV were stored at −80 °C and thawed on 
ice prior to use.  
3.2.2. Formulation of synthetic mucus-penetrating gene delivery nanoparticles 
For comparison with AAV diffusion in CF sputum, synthetic mucus-penetrating 
gene delivery nanoparticles were formulated as described previously.[452] Briefly, 5 kDa 
methoxy polyethylene glycol (PEG) N-hydroxysuccinimide (Sigma-Aldrich) was 
conjugated to 25 kDa branched polyethylenimine (PEI; Sigma-Aldrich) to yield PEG5k–
PEI copolymer. Nanoparticles were formed by the drop-wise addition of 9–10 volume of 
0.2 mg/ml GFP-encoding plasmid DNA controlled by the cytomegalovirus promoter 
(Clontech) to 1 volume of a swirling polymer solution containing 25% unmodified PEI 
and 75% PEG5k–PEI copolymer, at an optimized nitrogen to phosphate ratio of 6. Twenty 
percent of the plasmid DNA used to assemble nanoparticles was fluorescently labeled by 
68 
 
Cy3 dye using the Mirus Label IT Tracker Intracellular Nucleic Acid Localization Kit 
(Mirus Bio). 
 
3.2.3. CF sputum sample collection and biochemical assay 
CF sputum samples were collected under written informed consent, in accordance 
with the Johns Hopkins Institutional Review Board (IRB). Spontaneously expectorated 
sputum samples were collected from patients visiting the Adult Cystic Fibrosis Center at 
Johns Hopkins University. Particle tracking experiments were conducted using samples 
stored at 4°C immediately after collection for up to 24 hours, based on our prior 
confirmation that the barrier properties of freshly collected sputum are maintained in this 
condition [447, 466]. To reduce the effects of salivary contamination, any sample with a 
visible quantity of saliva was excluded. Patients involved in this study received no 
mucolytics other than Pulmozyme® (i.e. dornase alfa) and/or hypertonic saline as part of 
their standard treatment regimen.  
The percent solids content and mucin concentration of sputum samples were 
determined using previously reported methods [466]. For solids content, sputum samples 
were frozen in liquid N2 and placed in a lyophilizer (FreeZone 4.5 Plus; Labconco) for at 
least 12 hours to completely extract water within individual samples. The percent solids 
content is defined as the ratio of mucus mass before and after the lyophilization. Mucin 
concentration was  determined based on the reaction between 2-cyanoacetamide (Sigma-
Aldrich) with O-linked glycoproteins (i.e. mucin) followed by a fluorometric assay, as 




3.2.4. Multiple particle tracking in CF sputum 
The motions of AAV or synthetic mucus-penetrating gene delivery nanoparticles 
in sputum were tracked by fluorescent video microscopy and quantified by MPT analysis 
using a software custom-written in MATLAB (Mathworks), as previously reported [457, 
467]. 
 
3.2.5. In vitro transduction 
Human CF bronchial epithelial immortalized cell line[468] (CFBE41o-; gift from 
Drs. Cebotaru and Guggino from Johns Hopkins University) and primary CF human 
bronchial epithelial cells expressing the F508del mutant cystic fibrosis transmembrane 
conductance regulator (CFTR) (CF HBE) were used for in vitro transduction studies. The 
University of Alabama at Birmingham IRB approved the use of primary cells. CFBE41o- 
cells were grown in Minimum Essential Media with 10% fetal bovine serum, L-
glutamine, penicillin/streptomycinin and puromycin (5 µg/mL). Primary CF HBE cells 
were expanded using co-culture with irradiated fibroblasts (R&D systems) and 
conditional reprogramming via media containing a rho-associated protein kinase 
inhibitor.[469, 470] CFBE41o- or primary CF HBE cells were grown in 0.33 cm2 
polyester membrane transwell inserts (Corning) at an ALI for 4-6 weeks until terminally 
differentiated. Once the ALI was established, CFBE41o- or primary CF HBE cells were 
maintained in the above-described growth media or PneumaCult-ALI Maintenance 
Medium (Stemcell Technologies), respectively. A 5 µL suspension of 2 x 109 AAV 
vector genomes, either AAV1, AAV6 or AAV6-K531E, packaged with a gene encoding 
EGFP (i.e. scAAV-EGFP) were administered to the apical surface of the fully 
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differentiated ALI cultures at a multiplicity of infection (MOI) of 5000 to evaluate in 
vitro transduction efficiency. After incubation overnight with AAV, 100 µL of PBS was 
added to the apical chamber of inoculated cultures, incubated for 30 minutes at 37ºC, and 
washed via aspiration. 
We adapted a previously reported protocol to induce mucus hypersecretion in 
CFBE41o- ALI cultures.[471] Briefly, 5 µL of CSS was added to both the apical and 
basolateral compartments and incubated overnight. The CSS solution was prepared by 
high speed centrifugation (21,000 xg) for 1 hour of 2.5 mL sputum pooled from 5 CF 
patients, followed by filtration through a 0.2 µm ELF spin-filter (Molecular Probes). 
Apical mucin content of CFBE41o- ALI cultures was fluorometrically determined using 
the identical method used for the analysis of CF sputum. To remove apically secreted 
mucus from primary CF HBE ALI cultures, the apical chamber was incubated with 100 
µL of PBS at 37ºC for 30 minutes, followed by removal via aspiration. GFP transgene 
expression was imaged using a confocal LSM 510 microscope (Zeiss) at 10× and 20× 
magnification, and quantified using a custom-written software in MATLAB. To avoid 
artifacts presented by differences in focus between images, we used automated focusing 
(available in Zeiss Zen software) of DAPI nuclear staining and captured all images at this 
focal plane. Six or more randomly selected image regions were taken of each insert and 
used for quantification.  The percentage of GFP coverage was defined as the GFP-
positive area divided by the total cell-covered surface area and the total GFP intensity 
was quantified as the average of total pixel intensity units for each data set. Prior to 
quantitative analysis, all images were normalized by fluorescence of untreated control 




3.2.6. In vivo transduction 
All animals were treated in accordance with the policies and guidelines of the 
Johns Hopkins University Animal Care and Use Committee. Four-week old, congenic 
C57BL/6N transgenic mice with airway-specific overexpression of the epithelial sodium 
channel β-subunit (βENaC, gene Scnn1b) (i.e. Scnn1b-Tg mice)[472] were used for in 
vivo transduction studies. To evaluate the distribution and overall level of transgene 
expression in the lungs of Scnn1b-Tg mice, a 50 μL solution of 2 x 1010 AAV packaged 
with a gene encoding luciferase-YFP fusion protein (i.e. ssAAV-Fluc-YFP) were 
delivered intratracheally using a microsprayer (MicroSprayer Aerosolizer Model IA-1C; 
Penn-Century; n = 3 and 6 mice per group for assessing the distribution and overall level 
of transduction, respectively). Animals were sacrificed 2 weeks post-administration to 
determine the distribution of YFP transgene expression in airways/airspace as well as 
luciferase activity of whole lung homogenates, a measure of overall transgene expression 
level. For the distribution study, lungs were harvested, flash-frozen in OCT and 
cryosectioned using a CM1950 cryostat (Leica Biosystems). Slides were 
immunologically stained using an AF488-conjugated GFP monoclonal antibody (Santa 
Cruz Biotechnology) and DAPI, and subsequently imaged using a confocal LSM 510 
microscope under 10× and 20× magnification. Four or more randomly selected image 
regions were taken from 3 lung tissue sections from regions of the airways and airspace 
(total images per animal = 4 x 3 = 12) for the quantification of gene expression 
distribution.  To quantitatively assess the coverage of YFP transgene expression in 
airways/airspace, custom software written in MATLAB was used where images were 
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blinded and airway regions were manually determined based on DAPI staining. The 
boundaries of airway and non-airway regions (i.e. anywhere outside of selected airway 
regions) were further refined using automated image thresholding. Percentage of YFP 
coverage was defined as the YFP-positive airway or airspace area divided by the total 
area of a respective compartment. Prior to quantitative analysis, all images were 
normalized by fluorescence of untreated Scnn1b-Tg lung tissue to eliminate the 
contribution of autofluorescence. To directly visualize mucus plugs in the airways of 
Scnn1b-Tg mice, slides were immunologically stained with anti-MUC5B (Santa Cruz 
Biotechnology; 5B#19-2E:sc-21768) and anti-MUC5AC (ThermoFisher; MA5-12178) 
antibodies. For fluorescent tagging of MUC5AC and MUC5B, a biotinylated anti-mouse 
IgG (Sigma-Aldrich) was used as a secondary antibody, followed by a staining with 
ExtrAvidin-Cy3 (Sigma-Aldrich). Luciferase activity on lung tissue homogenates was 
measured using a standard luciferase assay kit (ThermoFisher Scientific) and a 20/20n 
luminometer (Turner Biosystems) [450, 452]. The relative light intensity was normalized 
by total protein concentration measured by a standard bicinchoninic acid assay 
(ThermoFisher Scientific).  
 
3.2.7. Statistical analysis  
Data were analyzed with statistical tests including student’s t-test using SigmaPlot 
10.0 and a non-parametric Mann Whitney test using MATLAB R2014b. Multiple 
comparisons were performed by one-way analysis of variance (ANOVA) using 
MATLAB R2014b. Data were considered statistically significant when p < 0.05. The 





3.3.1. AAV diffusion in freshly collected CF sputum 
To assess the abilities of different AAV vectors to penetrate human airway 
mucus, we measured using MPT the diffusion rates of AF647-labeled AAV in freshly 
collected sputum samples spontaneously expectorated by CF patients.  
 
Figure 3.1 AAV diffusion in spontaneously expectorated CF sputum. (a) Representative 
trajectories of AAV1, AAV6 and AAV6-K531E in CF sputum. Trajectories show 10 seconds of 
AAV motions. Color bar indicates the time (t) of the trajectory in seconds. Scale bar = 1 µm. (b) 
Box-and-whisker plots of MSD1s of AAV1 and AAV6 in sputum samples collected from 8 
individual CF patients. Maximum whisker length is 1.5 times the interquartile range; outliers are 
shown as dots. (c) Box-and-whisker plots of MSD1s for AAV1, AAV6 and AAV6-K531E in all 




The percent solids content and mucin concentration of collected sputum samples were 7.4 
± 4.9% and 5.9 ± 1.6 mg/mL, respectively, in good agreement with previously reported 
values [466, 473]. We have previously confirmed that our method of AF647 labeling 
does not significantly alter the natural surface property and transduction efficiency of 
AAV [457]. Consistent with our prior observation [457], AAV1 displayed highly 
confined trajectories, indicating their entrapment within CF sputum. In contrast, AAV6 
traveled far greater distances over time (Figure 3.1a). Quantitatively, AAV6 consistently 
exhibited significantly greater diffusion rates, measured by mean squared displacement at 
a time scale of 1 second (MSD1s), compared to AAV1 in sputum samples collected from 
8 different CF patients (Figure 3.1b). MSD1s represents the average squared distances 
individual AAV travel within a 1 second time interval and is directly proportional to their 
diffusion rates [467].  
 
Figure 3.2. Synthetic and viral gene vector diffusion in spontaneously expectorated CF sputum. 
(a) Representative trajectories of synthetic mucus-penetrating gene delivery nanoparticles based 
on polyethylene glycol-conjugated polyethylimine (PEI-PEG)19 and AAV6 in CF sputum. 
Trajectories show ~10 seconds of gene vector motions. Color bar indicates the time (t) of the 
trajectory in seconds. Scale bar = 1 µm. (b) Box-and-whisker plots of MSD1s of PEI-PEG and 
AAV6 in sputum samples collected from 3 individual CF patients. Maximum whisker length is 
1.5 times the interquartile range; outliers are not shown. A Mann-Whitney test was used to 
compare MSD1s and there was no significant difference (p>0.05). 
Based on the median of MSD1s, AAV6 diffusion in CF sputum was enhanced by 3–10 
fold in comparison to AAV1. Of note, we found that AAV6 diffusion in CF sputum was 
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comparable to that of a synthetic gene delivery nanoparticle previously confirmed to 
efficiently penetrate CF sputum [452] (Figure 3.2). In order to further explore the 
differences in diffusion behaviors of AAV1 and AAV6 in CF sputum, we measured the 
diffusion rate of an AAV6 mutant, AAV6-K531E, which has been previously shown to 
confer AAV6 with an AAV1-like binding affinity to glycans [465]. The diffusion rates of 
AAV6-K531E in 5 different CF sputum samples were significantly lower than those of 
wild-type AAV6, and comparable to those of wild-type AAV1 (Figure 3.1c,d). We found 
that diffusion rates of AAV1 and AAV6 did not significantly correlate with solids content 
(i.e. percent dry weight) of sputum samples (R2 = 0.05), consistent with our prior 
observation with AAV2 [457]. 
 
3.3.2. Impact of apical mucus on in vitro AAV transduction  
Based on the significantly enhanced diffusion rates of AAV6 compared to AAV1 
in CF sputum (Figure 3.1), we next sought to determine the impact of secreted mucus on 
the abilities of different AAV vectors to penetrate to the underlying airway epithelial 
cells and mediate transgene expression in vitro. We first examined in vitro transduction 
efficiency of AAV1, AAV6 and AAV6-K531E in CFBE41o- cells, derived from a 
F508del homozygous CF patient, grown at an ALI where cells are differentiated into a 
mucus-secreting lung airway epithelium. Once fully differentiated, AAV-mediated GFP 
transgene expression was evaluated 2 weeks post-infection using confocal microscopy 
(Figure 3.3a-c). We found that AAV6-treated CFBE41o- cultures exhibited ~2-fold 
greater coverage and overall level of GFP transgene expression compared to AAV1-
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treated cultures, whereas both the coverage and overall level were comparable between 
AAV6-K531E- and AAV1-treated cultures (Figure 3.3d,e). 
 
Figure 3.3. In vitro transgene expression in human CFBE41o- ALI cultures. (a-c) Representative 
images of CFBE41o- ALI cultures transduced with AAV1, AAV6 and AAV6-K531E. Scale bar = 
50 µm. (d,e) Image-based quantification of AAV-mediated GFP transgene expression in terms of 
(d) overall level and (e) relative coverage in CFBE41o- ALI cultures (n = 6). (f) Mucin contents 
of CFBE41o- ALI cultures before and after CSS treatment. (g,h) Representative images of 
CFBE41o- ALI cultures transduced with AAV1 and AAV6 where cultures were pretreated 
overnight with CSS. (i,j) Image-based quantification of AAV-mediated GFP transgene expression 
in terms of (i) overall level and (j) relative coverage in CSS-pretreated CFBE41o- ALI cultures (n 
= 6). *p < 0.05; student’s t-test or one-way ANOVA. 
We then repeated the experiment using CFBE41o- ALI cultures treated to induce mucus-
hypersecretion. Mucus hypersecretion was established by incubating the cultures 
overnight with CSS solution rich in pro-inflammatory cytokines such as IL-1β, neutrophil 
elastase, and TNF- [474], which has been previously shown to induce mucus 
hypersecretion in human airway epithelial ALI cultures [471]. Mucus hypersecretion was 
confirmed by measuring the quantity of mucin collected from the apical surfaces of 
CFBE41o- cultures where the mucin level was ~3 fold greater in CSS-treated cultures 
than in untreated control cultures (Figure 3.3e). Subsequently, we compared the 
transduction efficiency of apically administered AAV1 and AAV6 in CSS-treated versus 
untreated CFBE41o- cultures. The AAV1-mediated coverage and overall level of GFP 
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transgene expression were significantly reduced in CSS-treated CFBE41o- cultures 
compared to untreated cultures, whereas AAV6 retained those readouts regardless of the 
CSS-induced mucus hypersecretion (Figure 3.3f-j).  
To further test the effect of secreted mucus on AAV transduction, we evaluated 
AAV transduction in primary CF HBE cells, harvested from F508del homozygous CF 
patients, grown at an ALI with or without the removal of apically secreted mucus. We 
found that while the coverage and overall level of GFP transgene expression mediated by 
AAV1 was significantly enhanced by washing the apical mucus with PBS, mucus 
removal did not affect the readouts when treated with AAV6 (Figure 3.4). Of note, the 
removal of apically secreted mucus restored AAV1-mediated transduction to levels 
comparable to AAV6 (Figure 3.4). 
 
Figure 3.4. In vitro transgene expression in primary CF HBE ALI cultures. (a-d) Representative 
images of GFP expression in primary CF HBE ALI cultures 2 weeks post AAV transduction. 
Prior to the treatment, cultures were either left unwashed (No Wash) or washed by PBS for the 
removal of the apically secreted mucus layer (PBS Wash). Scale bar = 50 µm. (e) Image-based 
quantification of AAV-mediated GFP expression in primary CF HBE ALI cultures with (+) or 
without (-) PBS wash (n = 3).  *p < 0.05; one-way ANOVA. 
 
3.3.3. In vivo AAV transduction in a mouse model of muco-obstructive lung disease  
 To determine if the mucus-penetrating property of AAV6 led to enhanced in vivo 
lung gene transfer, we compared the transduction efficiencies of AAV1 and AAV6 
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following administration via an aerosol-generating microsprayer to the lungs of Scnn1b-
Tg mice overexpressing βENaC in the airways. Scnn1b-Tg mice spontaneously develop 
disease symptoms reminiscent of muco-obstructive lung diseases, such as mucus 
hyperconcentration/plugging, chronic airway inflammation and airspace enlargement 
[472, 475]. We confirmed the presence of mucus plugs in the airways of Scnn1b-Tg mice 
via immunohistochemistry, which was also distinguished through luminal DAPI staining 
of immune cells and DNA found within mucus plugs (Figure 3.5).  For in vivo 
transduction studies, 2 x 1010 ssAAV-Fluc-YFP, either AAV1 or AAV6, in 50 µL PBS 
were administered into the lungs of Scnn1b-Tg mice. 
 
Figure 3.5. Mucus in the lungs of Scnn1b-Tg mice. Representative confocal images of mucus in 
the airways (a) versus the airspace (b). Cell nuclei and DNA are stained with DAPI (blue) and 
mucins are stained with anti-MUC5B/5AC Ab (red). 
The lung distribution of YFP transgene expression was visualized 2 weeks post-infection 
with AAV1 or AAV6, as shown in the representative confocal micrographs of proximal 
and distal airways (Figure 3.6a-h). The relative coverage of YFP transgene expression in 
the airway and airspace was quantitatively assessed using a custom-written MATLAB 
software. In comparing different, randomly selected regions of the lung, we observed a 
significantly greater YFP coverage in the mucus-covered/plugged airways (Figure 3.5a) 
of Scnn1b-Tg mice that intratracheally received AAV6 (28%), compared to the mice that 
received dose-matched AAV1 (13%) (Figure 3.6b, d and i). There was no significant 
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difference in YFP coverage following the treatment with AAV6 (5%) and AAV1 (3%) in 
the airspace devoid of mucus secretion (Figure 3.6i and E1b). 
 
Figure 3.6. In vivo transgene expression in the lungs of Scnn1b-Tg mice following intratracheal 
administration of AAV1 or AAV6. (a-h) Representative images of YFP expression (green) in the 
proximal (a-d) and distal airways/airspace (e-h). Cell nuclei are stained with DAPI (blue). 
Regions of the airway lumen where mucus plugs were observed are outlined in red. Scale = 200 
µm. (i) Image-based quantification of YFP expression coverage (n = 3 mice with 3-4 lung 
sections per mouse). (j) AAV-mediated luciferase expression quantified for whole lung 
homogenates (n =  6 mice). *p < 0.05; student’s t-test. 
We also determined the luciferase activity of the whole lung homogenates, an indicator of 
overall level of reporter transgene expression, from AAV1- and AAV6-treated Scnn1b-
Tg mice, which revealed a ~2-fold greater bioluminescence intensity in the lungs of 
AAV6- versus AAV1-treated Scnn1b-Tg mice (Figure 3.6j).  
 
3.4. Discussion 
 We have discovered that AAV6 is capable of efficiently diffusing through human 
CF sputum (i.e. mucus), which presents a critical extracellular barrier to effective inhaled 
gene therapy. In vitro studies in human non-primary and primary CF airway epithelial 
ALI cultures revealed that AAV6 gene transfer efficacy was not affected either by the 
presence of an endogenously secreted mucus layer or by induced mucus hypersecretion. 
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In contrast, AAV1 transduction was markedly inhibited by both steady-state or induced 
mucus, presumably as a result of its inability to penetrate this barrier. The mucus-
penetrating property of AAV6 was further confirmed in vivo. Inhaled AAV6 provided 
widespread and high-level transgene expression in the mucus-covered/plugged airways 
and the whole lungs, respectively, of a mouse model with airway mucus obstruction. This 
result agrees with our prior observations using synthetic mucus-penetrating drug and 
gene delivery nanoparticles that, unlike conventional mucoadhesive particles, exhibited 
widespread distribution and/or transgene expression in mouse lungs [447, 450-452, 476]. 
Importantly, the inhaled AAV6 mediated roughly 30% airway coverage of transgene 
expression, which is comparable to the percentage of human CF airway epithelial cells 
with CFTR transgene expression (~25%) that was previously shown to require for 
restoring normal mucus transport rates in vitro [37]. Overall, efficient mucus penetration 
is likely a crucial mechanism by which AAV6 may achieve therapeutically relevant lung 
gene transfer. 
In contrast to our observations, mucin was previously shown not to inhibit AAV1 
transduction in vitro [465]. The discrepancy is likely due to the markedly lower mucin 
concentrations employed in this earlier study (≤ 0.5 mg/mL) [477], which is about an 
order of magnitude or more lower than the concentrations in naturally or pathologically 
secreted airway mucus collected from human subjects or ALI cultures of primary CF 
HBE [206, 213, 466, 478, 479]. It should be noted that unlike an aqueous mucin solution, 
a mucus gel can trap nano-sized objects, such as AAV, via multivalent adhesive 
interactions as well as steric obstruction [447, 449]. We also showed that, out of the 6 
different capsid residues between AAV1 and AAV6, a single amino acid K-to-E 
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substitution at the 531 position of the AAV6 capsid caused the mutant AAV6 (i.e. 
AAV6-K531E) to behave like AAV1 [465], a finding confirmed in airway mucus in vitro 
and ex vivo. We have previously demonstrated that heparan sulfate binding may be at 
least partially responsible for the adhesion of AAV2 to CF sputum [457]. However, it is 
unlikely the case here as it has been shown previously that AAV6 binds to heparan 
sulfate, whereas AAV1 and AAV6-K531E do not [465, 480]. These findings suggest that 
glycan-mediated entrapment mechanisms may vary among AAV serotypes. In future 
studies, we aim to further explore the nature of interactions between different AAV 
serotypes and the glycans present on airway mucins. 
 The results of this study demonstrate the importance of using preclinical models 
that mimic key pathophysiological conditions of patients affected with muco-obstructive 
lung diseases in evaluating the efficacy of inhaled gene therapy. Ex vivo and in vitro 
experiments were designed to evaluate the ability of AAV6 to overcome pathological 
human airway mucus (i.e. CF sputum) and subsequently achieve efficient transduction of 
human airway epithelium. Past studies comparing the gene transfer efficacy of different 
AAV serotypes in human ALI cultures may have been affected by the large volumes (50 
- 200 µL) [109, 112, 481-483] applied on the apical surface during AAV administration, 
which dilute and potentially alter the barrier properties of apically secreted mucus. We 
thus used a small volume (i.e. 5 µL) in our experiments to minimize this issue. Most 
preclinical in vivo studies have also been conducted using healthy animals lacking critical 
pathological features in the lung [449]. In contrast, we evaluated the in vivo gene transfer 
efficacies of AAV serotypes possessing different abilities to penetrate the airway mucus 
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barrier using an established animal model of CF and COPD characterized by airway 
mucus plugging.  
3.5. Conclusion 
 We found that, by using a relevant pre-clinical mouse model of muco-obstructive 
lung diseases and in vitro model of primary CF HBE cells, AAV6 exhibits better mucus 
penetrability and more widespread transduction of airway epithelial cells compared to 
AAV1. Future studies should address the persistence of transgene expression as well as 
the ability to re-administer AAV without concern of therapy-inactivating 
immunogenicity. Towards this end, development and/or identification of a library of 
AAV vectors that possess the mucus-penetrating property while retaining high-level 
transduction efficiency would allow for serial vector administration for life-long 
therapeutic effects. In summary, we have demonstrated that the ability of AAV6 to 
penetrate the mucus barrier is a critical mechanism by which it achieves robust gene 
transfer to the lung airways. Our results underscore the importance of vectors used in 
inhaled gene therapy to overcome the mucus barrier, which is particularly reinforced in 
patients with muco-obstructive lung diseases. 
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Due to recent advances in identification of genetic loci and modifiers involved in 
development of muco-obstructive lung diseases, gene therapy has been considered an 
important, high-potential therapeutic strategy [449]. Muco-obstructive lung diseases (e.g. 
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma) has the 
central pathology of mucus obstruction in the lung airways caused by various non-
mutually exclusive factors such as hyper-concentrated mucus and dehydrated airway 
surface liquid (ASL), impaired mucociliary clearance (MCC), bacterial infection, 
inflammation, and dysfunctional epithelial ion channels [447, 449, 484]. Mucus 
obstruction also serves as a biological barrier that hinders delivery of therapeutics to the 
underlying epithelium [196, 447, 449, 479, 485], limiting the attractiveness of the lungs 
as one of the most straightforward targets for gene delivery (i.e. inhalation) (Griesenbach, 
Curr Opin Mol Ther, 2005). As such, inhaled gene therapy of muco-obstructive lung 
diseases has not successfully translated to the clinics to date [196, 449]. CF, an inherited 
genetic disease hallmarked by muco-obstructed lungs, has received much attention in 
gene therapy due to well-defined therapeutic target (i.e. CF transmembrane conductance 
regulator gene, or CFTR) and aforementioned direct access to the lungs, where the most 
life-threatening symptoms are manifested [486, 487]. Over 25 clinical trials of inhaled 
viral and non-viral gene therapy have failed to show clinical benefits largely due to 
inefficient gene transfer to the airway epithelium [449, 487]. Indeed, many commonly 
used viral vectors and conventionally formulated non-viral vectors cannot efficiently 
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penetrate through CF sputum [202, 210, 211], resulting in inadequate transgene 
expression both spatially and temporally. We believe there are two key considerations 
that may have been beneficial to their outcome – 1) the use of phenotypically relevant 
(i.e. muco-obstruction) animal models and 2) mucus-penetrability of gene vectors.  
We previously demonstrated that mucus-penetrating DNA nanoparticles (DNA-
MPP) composed of poly(β-amino ester) (PBAE) and polyethylene glycol (PEG) provided 
widespread distribution and transgene expression in the lungs of a healthy mouse model 
[488]. For clinical relevance, however, it is critical that DNA-MPP perform as such in the 
lung conditions relevant to muco-obstructive lung diseases. Therefore, the aim of present 
study was to demonstrate the safety and effectiveness of DNA-MPP in the β-epithelial 
Na+ channel-overexpressing transgenic (Scnn1b-Tg) mice, a mouse model of muco-
obstructive lung disease.  
The muco-obstructed lung phenotype in the Scnn1b-Tg mice is caused by clara 
cell-specific overexpression of the Scnn1b gene, which encodes for the β-subunit of the 
epithelial sodium channel (ENaC) [472]. Overexpression of the β-subunit leads to 
increased interaction with the two remaining subunits of ENaC (i.e. α and γ), 
subsequently over-production of airway ENaC. The increased flux of Na+ ion into the 
epithelium causes CF-like lung disease in this mouse model with features including 
dehydration of ASL, impaired MCC, mucus hypersecretion, bacterial infection, and 
inflammation [472, 489]. In human CF epithelium, ENaC is intact or in some cases 
hyper-activated on top of CFTR deficiency, which leads to an imbalance of ions and fluid 
that makes CF airway surfaces vulnerable to dehydration and impaired MCC [490]. 
Exacerbations in many non-CF airway diseases result from impaired MCC as well, which 
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underscores the therapeutic importance of ENaC modulation [242, 314, 491]. To this end, 
multiple drugs that target ENaC are currently in the pipeline [492]. Therefore, the 
Scnn1b-Tg mouse model serves as an essential tool for validation of inhaled gene vectors 
as well as the effects of ENaC modulation in vivo for muco-obstructive lung diseases 
[493]. We hypothesized that DNA-MPP can safely achieve widespread distribution and 
robust transgene expression in presence of muco-obstruction in the airways of the 
Scnn1b-Tg mice. Further, we aimed to deliver shRNA-encoding DNA plasmid to 
modulate the expression of ENaC in order to ameliorate the muco-obstruction. 
4.2. Materials and Methods 
4.2.1. Reagents 
Reagents were purchased from different companies as follows: 1,4-butanediol 
diacrylate, 5-amino-1-pentanol, 4-amino-1-butanol, and 1-(3-aminopropyl)-4-
methylpiperazine (C4) from Alfa Aesar; 1,3-diaminopropane (C1) and 2,2-dimethyl-1,3-
propanediamine (C2) from Sigma-Aldrich; N-(3-aminopropyl)pyrrolidine (C3) from 
Acros Organics; 2-(3-aminopropylamino)ethanol (C5) from Oakwood Chemical; N-(3-
aminopropyl)diethanolamine (C6) and 1,11-diamino-3,6,9-trioxaudecane (C7) from 
Tokyo Chemical Industry; and methoxy-polyethylene glycol (PEG)-succinimidyl 
succinate from JenKem Technology. Solvents were purchased as follows: ethyl ether 
anhydrous from Fisher Scientific; and dimethyl sulfoxide anhydrous (DMSO) and 
tetrahydrofuran (THF) from Sigma-Aldrich. 
4.2.2. Polymer synthesis 
PBAE polymers were synthesized as previously described [488]. Briefly, 1,4-
butanediol diacrylate and 4-amino-1-butanol were reacted at a 1.1:1 ratio to synthesize 
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high molecular weight uncapped polymer (6 ± 0.2 kDa) or at a 1.2:1 ratio to synthesize 
low MW upcapped polymer (4 ± 0.2 kDa) at 95 °C for 20 hours. Polymers were then 
purified by dropwise precipitation into cold anhydrous diethyl ether. The mixture was 
vigorously vortexed and centrifuged at 2,000 rpm for 3 minutes to pellet the polymer. 
The supernatant was discarded, then the polymer was washed twice more in anhydrous 
diethyl ether. The resulting polymer was dried under vacuum for at least 72 hours, then 
the molecular weight was estimated by nuclear magnetic resonance (NMR). The end 
acrylate groups were capped with 30 molar equivalents of 2-(3-
aminopropylamino)ethanol or other capping groups (Figure 4.1) at 100mg/ml in THF 
overnight at room temperature followed by the cold ether purification and vacuum-
mediated solvent removal process. Complete end-capping and purity were confirmed by 
the absence of the diacrylate peaks in the NMR spectrum. The end-capped PBAE 
polymer was dissolved in DMSO at 100mg/ml, and stored at -20 °C. 
For the synthesis of PEGylated PBAE polymers, the low MW uncapped polymer 
synthesized with abovementioned steps was end capped with C1, resulting in P1C1 
polymer. Then, 2.05 molar equivalent of 5 kDa methoxy-PEG-succinimidyl succinates 
were reacted with the two terminal primary amine groups at both ends of P1C1 at 
100mg/ml in THF for 24 hours at room temperature (Figure 4.1). The resulting product 
was washed with anhydrous diethyl ether as described above, dried under vacuum, 






4.2.3. 1H nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectra of PBAE and PEG-PBAE dissolved in deuterated methanol 
(MeOH-d4; Cambridge Isotope Laboratories) were recorded on a Bruker spectrometer 
(500 MHz). 1H chemical shifts were reported in ppm (δ) and the MeOH peak was used as 
an internal standard. Data were processed using Mest-ReC software. 
4.2.4. DNA-NP formulation and characterization 
The luciferase-expressing plasmid driven by a human beta-actin promoter (pBAL) 
was produced by Copernicus Therapeutics, and the green fluorescent protein (GFP)-
encoding plasmid driven by a cytomegalovirus (CMV) promoter (pEGFP) was purchased 
Capping Group (C) 
Figure 4.1. Chemical structure of monomers and polymers used to create DNA-MPP 
formulations. Core polymer, PBAE, is comprised of a combination of P1 and a C (capping 
group). PEG-PBAE is comprised of short molecular weight P1, C1, and 5 kDa methoxy PEG. 
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from Clontech Laboratories. CFTR-expressing plasmid driven by chicken beta-actin 
promoter was a kind gift from Dr. Liudmila Cebotaru. shRNA-expressing plasmid DNA 
against alpha subunit ENaC (Scnn1a location 1498, target sequence 
ggcgaattattctcagttcca), driven by H1 promoter, was purchased from Genecopoeia. The 
plasmids were expanded by transformation into appropriate E.coli strains and isolated by 
using Endofree Plasmid Giga Kit (Qiagen). Downregulation of alpha ENaC was validated 
in vitro, in M-1 mouse kidney epithelial cell line using Lipofectamine 3000. For 
assessment of DNA-NP distribution in mouse lungs, Label IT® Tracker Intracellular 
Nucleic Acid Localization Kit (Mirus Bio) was used to fluorescently label plasmid DNA 
with a Cy3 fluorophore. DNA-CP and DNA-MPP were formulated as previously 
described [280]. We characterized the hydrodynamic diameter and polydispersity index 
of DNA-NPs in water by dynamic light scattering (DLS), and the ζ-potential was 
measured in 10 mM NaCl at pH 7.0 by laser doppler anemometry using a Zetasizer Nano 
ZS (Malvern Instruments). To assess the stability of DNA-NP in physiologically relevant 
conditions, DNA-CP and DNA-MPP were incubated in bronchoalveolar lavage (BAL) 
fluid at 37 °C for 4 hours, with DLS measurements at 0, 5 minutes, 1, 2, and 4-hour 
timepoints. After observing rapid aggregation in BALF, DNA-CP was ruled out for 
further characterization. 
To test the DNA compaction of the DNA-MPP, conventional gel retardation assay 
was performed. 100 ng of various plasmid DNA used in this study (shENaC, pBAL, and 
pEGFP) and DNA-MPP carrying the respective plasmid DNA were mixed with 6X DNA 
loading dye (ThermoFisher) and loaded onto a 0.8 % agarose gel pre-stained with SYBR 
safe (ThermoFisher), and run for 30 minutes at 50 V. Also, DNA protection was assessed 
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by the same gel electrophoresis method after incubating the plasmid DNA and DNA-
MPP with 2 U of DNase I (ThermoFisher) for 15 minutes at 37 °C followed by addition 
of 50 mM EDTA at 65 °C to deactivate the DNase activity. To induce de-compaction of 
the MPP, samples were incubated with heparin (Sigma Aldrich) at a 3:1 (w/w) ratio of 
heparin to DNA at room temperature for 10 minutes, followed by agarose gel 
electrophoresis. Gels were imaged using a Chemi-Doc imaging system (Bio-RAD). 
4.2.5. Multiple Particle Tracking 
Multiple particle tracking (MPT) is a well-established method to quantify the 
mean square displacements (MSDs) of fluorescently labeled particles, as previously 
described. CF mucus freshly expectorated from CF patients were collected from the 
Johns Hopkins University Adult Cystic Fibrosis Center under written informed consent, 
in accordance with the Johns Hopkins Institutional Review Board. All experiments were 
conducted using samples stored at 4 °C immediately after collection for up to 24 hours. 
Any sample with a visible quantity of saliva was excluded to reduce the effects of 
salivary contamination. A 1 μl solution of fluorescently labeled DNA-NPs at a plasmid 
DNA concentration of 1 μg/ml was added to 30 μl of CF mucus, placed in custom-made 
microwells, and equilibrated for 30 minutes at room temperature. Movies were recorded 
over 20 s at an exposure time of 66.7 ms by an Evolve 512 EMCCD camera 
(Photometrics) mounted on an inverted epifluorescence microscope (Axio Observer D1; 
Carl Zeiss) equipped with a 100×/1.46 N.A. oil-immersion objective. Movies were then 
analyzed using a custom-made MATLAB code (MathWorks) to simultaneously extract x, 
y coordinates of the hundreds of DNA-NP centroids and calculate individual and median 
mean square displacement as a function of timescale [467]. To minimize the effect of 
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dynamic error in our measurement, we calculated the MSD at 1 s, a timescale previously 
established to be long enough to minimize dynamic error while allowing for tracking of 
DNA-NPs without losing a large number of the fast-moving population in the z direction. 
The theoretical diffusion rates of DNA-NPs in water were calculated using the Stokes–
Einstein equation, as previously described [467]. 
4.2.6. BAL fluid collection 
To collect BAL fluid, mice were euthanized by deep isoflurane anesthesia and the 
lungs were carefully harvested. A narrow micropipet tip connected to a 1 ml syringe was 
inserted into the trachea and lavage was performed with 1 ml of PBS, and then repeating 
twice more to collect total volume of ~3 ml. Cells were pelleted by centrifugation at 300 
x g for 5 minutes at 4 °C and the cell-free supernatant was collected and stored at 80 °C 
for ELISA, or lyophilized for mucin analysis. BAL cells were resuspended in 1 ml of 
PBS and total number of cells were counted with a hemocytometer. The lyophilized 
supernatant was reconstituted with 1 ml of ultrapure water for quantification of O-linked 
glycoproteins to approximate the mucin concentration by using the previously described 
method [466].  
4.2.7. Animal studies 
Mice were treated in accordance with the policies and guidelines of the Johns 
Hopkins University Animal Care and Use Committee. The Scnn1b-Tg mice used in this 
study has been extensively characterized for use in CF research [346, 472, 494-497] and 
were kind gift of Dr. Richard Boucher of University of North Carolina at Chapel Hill. 
The colony was maintained on a mixed genetic background (C3H/HeN x C57BL/6N), 
and Scnn1b-Tg mice were identified by genotyping service from TransnetYX, Inc. 
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Wildtype (WT) littermates were used as controls in all studies. Mice were anesthetized in 
2% isofluorane chamber. 4-week old mice were used for all in vivo studies. To assess the 
DNA-NP distribution and distribution of transgene expression in the mouse lungs, a 50 μl 
suspension of DNA-NPs carrying Cy3-labeled plasmid DNA or pEGFP, respectively, 
was administered intratracheally by using a microsprayer (Model IA-1C, Penn-Century) 
at the plasmid DNA concentration of 0.5 mg/ml (n=3 per group). Mice were killed 1 hour 
or 48 hours after the administration to assess distribution of DNA-NP or transgene 
expression, respectively. For DNA-NP distribution studies, lungs were perfused with 
PBS, fixed with 4% paraformaldehyde (PFA) overnight at 4 °C, and sequentially 
incubated in 10%, 20%, and 30% sucrose solutions for two days each at 4 °C, prior to 
embedding in OCT. The lungs were cryosectioned using a CM1950 cyrostat (Leica 
Biosystems), followed by DAPI staining (ProLong® Gold Antifade with DAPI, 
ThermoFisher) and imaging with an inverted epifluorescence microscope (Axio Observer 
D1, Carl Zeiss) at 10x magnification. For transgene expression distribution studies, lungs 
were perfused with PBS, harvested, then carefully filled with 1:1 mixture of PBS and 
OCT, immediately followed by embedding in cryomold. The lungs were cryosectioned, 
fixed in ice-cold 100% acetone, blocked with Block-Aid agent (ThermoFisher), and 
immunologically stained overnight at 4 °C using an anti-GFP antibody tagged with Alexa 
488 fluorophore (Biolegend) diluted in 1% bovine serum albumin/0.3% Triton X-
100/PBS solution. After washing with PBS three times, the slides were stained with 
DAPI for imaging with a confocal LSM 710 microscope (Carl Zeiss) under 10x or 20x 
magnification. Lung sections from untreated mice were processed the same way and used 
to determine the background fluorescence with the microscope settings. Image-based 
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quantification of distribution of DNA-NP and transgene expression was performed with a 
custom-written JAVA code. To assess the overall level of in vivo transgene expression, 
DNA-CP or DNA-MPP carrying pBAL were administered to WT littermate or Scnn1b-
Tg mice at 50 μl of fixed volume. After 1 week, the lungs were harvested and 
homogenized to measure luciferase activity as previously described [488]. The RLU was 
normalized by total protein concentration measured by BCA assay. For western blotting, 
lung homogenate was prepared for each mouse and 40 mg of protein were loaded into 
each well of Novex Tris-Glycine gel (ThermoFisher) and run at 120 V for 1.5 hrs. Protein 
was transferred to nitrocellulose membranes and blocked with bovine serum albumin 
(BSA) for one hour, followed by overnight primary antibody incubation at 4 °C. The 
membranes were washed three times with PBS, and were incubated with secondary 
antibodies for 1 hour at room temperature. Membranes were washed with PBS three 
times, and ECL substrate (Promega) was applied for visualization of protein bands with 
Chemi-Doc imaging system. 
4.2.8. Hypertonic saline treatment 
7% NaCl solution was prepared and sterile-filtered with 0.22 μm syringe filter. 4-
week old Scnn1b-Tg mice were anesthetized under 2% isoflurane, then 7% NaCl or equal 
volumes of vehicle (i.e. ultrapure water) was administered (1 μl/g body weight, three 
times per day) via intratracheal instillation for 1 week. A day after the last treatment, 
DNA-MPP containing the shENaC plasmid DNA was delivered via intratracheal 
instillation with a microsprayer. 
93 
 
4.2.9. In vitro studies 
Primary CF human bronchial epithelial cells expressing the homozygous F508del 
mutant CFTR (CF HBE) were used for in vitro transfection studies. The University of 
Alabama at Birmingham IRB approved the use of primary cells. Primary CF HBE cells 
were expanded using co-culture with irradiated fibroblasts (R&D Systems) and 
conditional reprogramming via media containing a rho-associated protein kinase 
inhibitor. Primary CF HBE cells were grown in 0.33 cm2 polyester membrane 
Transwell® inserts (Corning) coated with NIH 3T3 fibroblast conditioned media until 
fully confluent. Primary CF HBE cells were maintained in differentiation media for at 
least 4-6 weeks until terminally differentiated. An 8 μL suspension of DNA-CP or DNA-
MPP at 0.1 mg/ml concentration was administered to the apical surface of the fully 
differentiated ALI cultures to evaluate in vitro transfection efficiency. After two days, the 
Transwell® inserts were cut out with a micro-scalpel and placed onto a glass slide and 
coverslip for fluorescence imaging. To avoid artifacts presented by differences in focus 
between images, we used automated focusing (available in Zeiss Zen software) of DAPI 
nuclear staining and captured all images at this focal plane. Six or more randomly 
selected image fields were taken of each insert and used for quantification. The 
percentage of GFP coverage was defined as the GFP-positive area divided by the total 
cell-covered surface area, and the total GFP intensity was quantified as the average of 
total pixel intensity units for each dataset. Prior to quantitative analysis, all images were 
normalized by fluorescence of untreated control ALI cultures to eliminate the 




Cells grown on Transwell® inserts were stained for detection of transgene 
expression via confocal microscopy. Each Transwell® insert was washed with PBS three 
times, and then fixed with 4% paraformaldehyde overnight at 4 °C. Cells were washed 
with PBS again, and by using a micro-surgical knife (MSP, Cat# 7503), the Transwell® 
membranes were carefully cut out. For blocking unspecific binding of antibodies and cell 
permeabilization, each membrane was placed cell-side down on a 20 μl drop of 6% 
normal goat serum/0.05% Triton X-100 on a piece of parafilm for 30 minutes. Primary 
antibody was diluted to appropriate concentration in 3% normal goat serum/0.025% 
Triton X-100, and the Transwell® membrane was again placed cell-side down on a 20 μl 
drop of the antibody solution on parafilm for overnight incubation at 4 °C. Membranes 
were washed three times with PBS, and secondary antibody in 3% normal goat 
serum/0.025% Triton X-100 at 1:1000 dilution was applied for 1 hour. Membranes were 
washed with PBS three times, and were mounted on a glass slide and coverglass with 




4.3.1. Characterization of DNA-MPP 
We first engineered a DNA-loaded mucus-penetrating particle (DNA-MPP) 
platform for inhaled gene therapy of muco-obstructive lung diseases, using a method that 
we had previously established [488]. Specifically, a mixture of poly(β-amino ester) 
(PBAE) and polyethylene glycol (PEG)-conjugated PBAE polymers at an optimized ratio 
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was used to compact plasmids encoding various reporter or therapeutic nucleic acids, 
including luciferase (~5 kb), GFP (~4.7 kb) or  shRNA against ENaC (~6.5 kb). In 
parallel, we formulated mucus-impermeable DNA-loaded conventional particles (DNA-
CP) using PBAE polymers only. We first confirmed that all the DNA-MPP formulations 
exhibited mucus-penetrating particle properties, including small particle diameters (~ 50 
nm) and near neutral surface charges [488], regardless of the type/size of plasmid 
payloads (Table 4.1). In comparison, DNA-CP possessed larger particle sizes (> 100 nm 
in diameters) and highly cationic surfaces (ζ-potentials of ~ 30 mV) (Table 4.1). We then 
conducted gel electrophoretic retardation assay where we found that all three plasmids 
were stably packaged into DNA-MPP, as evidenced by their complete retention within 
the wells of the gel (Figure 4.2A). Moreover, DNA-MPP were capable of protecting 
plasmid payloads from enzymatic degradation by DNase, while free plasmids were 
completely degraded (Figure 4.2B). We next confirmed that DNA-MPP retained their 
small particle diameters (~50 nm) in bronchoalveolar lavage (BAL) fluid at 37 ˚C as least 
up to 4 hours (Figure 4.2C), indicating an excellent colloidal stability in a physiologically 
relevant lung environment. In contrast, DNA-CP immediately aggregated as soon as the 
incubation commenced, reaching microns of sizes within an hour (Figure 4.2C). 
Table 4.1. Characterization of DNA-NP. Size and surface charge 




4.3.2. In vivo distribution of nanoparticles and transgene expression 
We previously demonstrated that DNA-MPP provided widespread distribution 
and transgene expression in the lungs of healthy mice [488]. However, it is critical for its 
clinical relevance that DNA-MPP perform as such in the lung conditions relevant to 
muco-obstructive lung diseases. We thus investigated in vivo behaviors of DNA-MPP, in 
comparison to DNA-CP, in the lungs of Scnn1b-Tg mice, a mouse model that emulates 
the phenotypic hallmarks of muco-obstructive lung diseases, including mucus plugging 
and chronic inflammation [472]. We first compared lung distribution of Cy3-labeled 
DNA-CP and DNA-MPP following a single intratracheal administration via a 
microsprayer. It appeared that some amounts of both formulations were inevitably found 
entrapped within the mucus plugs established in the airways of Scnn1b-Tg mice one hour 
after the administration (Figures 4.3A-C). However, while DNA-CP were sparsely 
distributed or rarely observed in the airway lumen (Figure 4.2B), DNA-MPP exhibited 
widespread and uniform distribution throughout the airways and airspace (Figure 4.3C). 
We next investigated whether the observed particle distribution pattern translated to the 
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Figure 4.2. In vitro characterization of DNA-loaded nanoparticles. Electrophoretic analysis of 
(A) complexation and (B) protection (against enzymatic degradation by DNase) of plasmids. 
Lane 1: GFP-encoding plasmid; 2: pBAL-encoding plasmid; 3: shENaC-encoding plasmid; 4: 
GFP-MPP; 5: pBAL-MPP; 6: shENaC-MPP. (C) Colloidal stability of DNA-CP and DNA-MPP 




distribution of transgene expression. To do this, we identically treated Scnn1b-Tg mice 
with a single dose of DNA-CP or DNA-MPP carrying GFP-encoding plasmids and 
assessed the transgene expression at 48 hours post-administration via confocal 
microscopy of lung tissue sections (Figure 4.3D-F). In good agreement with the particle 
distribution profile, GFP transgene expression was sporadic in the lungs of mice treated 
with DNA-CP (Figure 4.3E), whereas DNA-MPP provided widespread transgene 
expression throughout the lungs (Figure 4.3F), even in an entire lobe in several cases 
(Figure 4.4). Of note, no fluorescence was observed in untreated lungs (Figures 4.3A, D). 
Image-based quantification revealed that the airway coverages of GFP transgene 
expression mediated by DNA-CP and DNA-MPP were ~5% and ~35%, respectively 
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(Figure 4.3G). Likewise, DNA-MPP exhibited approximately 8-fold greater coverage of 
transgene expression compared to DNA-CP in the airspace (Figure 4.3H).  
 
No Treatment DNA-CP DNA-MPP A B C 








Figure 4.3. In vivo particle distribution and transgene expression in the lungs of Scnn1b-
Tg mice following a single intratracheal administration of DNA-loaded nanoparticles. 
Representative confocal images demonstrating particle distribution in (A) untreated lung 
and lungs treated with (B) DNA-CP or (C) DNA-MPP. Red: DNA-CP or DNA-MPP; 
Blue: cell nuclei; White arrows: mucus plugs. Representative confocal images 
demonstrating reporter transgene expression in (D) untreated lung and lungs treated with 
(E) DNA-CP or (F) DNA-MPP. Green: GFP transgene expression; Blue: cell nuclei. 
Aw: airway; Scale bars = 100 μm. Quantification of transgene expression coverage in 
(G) airways and (H) airspace. Data represent mean ± S.E.M. Differences are statistically 
significant as indicated (***p < 0.001; student’s t-test). 
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4.3.3. Overall in vivo transgene expression and safety in chronically inflamed mouse 
lungs 
We subsequently investigated whether the widespread gene transfer enabled by 
DNA-MPP resulted in high-level overall transgene expression. Specifically, DNA-CP or 
DNA-MPP carrying luciferase-encoding plasmids (at 0.5 mg/ml plasmids in 50 μl) were 
administered intratracheally to the lungs of Scnn1b-Tg mice, and the lung tissues were 
harvested for homogenate-based luciferase assay seven days after the administration. We 
found that DNA-MPP mediated about an order of magnitude greater luciferase activity 
compared to the level achieved by DNA-CP (Figure 4.5A). We then conducted a dose 
escalation study where single incrementing doses of DNA-MPP carrying luciferase-
Figure 4.4. Confocal image of a section of left lung of Scnn1b-Tg mouse treated with DNA-MPP 
carrying GFP plasmid DNA. Green: GFP; Blue: Nuclei; Scale bar: 500μm 
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encoding plasmids (i.e. 0.125 mg/ml to 2 mg/ml plasmids in 50 μl) provided dose-
dependent increase in the luciferase activity (Figure 4.5B). While the 1 mg/ml plasmid 
concentration provided significantly greater overall transgene expression (i.e. luciferase 
activity) compared to its half dose (i.e. 0.5 mg/ml) (Figure 4.5B), we elected to conduct 
further studies with the latter due to its in vivo safety established in healthy mouse lungs 
in our prior study [488]. We next evaluated the effect of repeated administration of DNA-
A 
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Figure 4.5. Overall level of in vivo transgene expression in the lungs of Scnn1b-Tg mice 
following intratracheal administration of DNA-loaded nanoparticles. (A) Comparison of 
transgene expression mediated by DNA-CP and DNA-MPP following a single administration. 
Transgene expression mediated by (B) incrementing or (C) repeated doses of DNA-MPP. (D) 
Total number of cells in BAL fluid following a single and repeated treatment(s) with DNA-MPP. 
Data represent mean ± S.E.M. Differences are statistically significant as indicated (*p < 0.05; **p 
< 0.01; One-way ANOVA or Student’s t-test). Histological H & E staining of lungs of (E) 
untreated wild-type (WT) littermate mice, (F) untreated Scnn1b-Tg mice and Scnn1b-Tg mice 
received (G) a single dose or (H) two doses of DNA-MPP. Scale bar = 200 μm 
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MPP and discovered that two doses given with one-week interval resulted in statistically 
significant amplification of the overall transgene expression level (Figure 4.5C). It is 
critical that DNA-MPP provides an acceptable safety in relevant disease conditions, such 
as in the readily inflamed lungs of patients with muco-obstructive lung diseases. We thus 
sought to test whether DNA-MPP further aggravated chronic inflammation established in 
the lung of Scnn1b-Tg mice by quantifying the total number of cells in BAL fluid. 
Consistent with a prior observation [472], the total cell count was markedly greater in the 
lungs of Scnn1b-Tg mice compared to the lungs of littermate wild-type mice (Figure 
4.5D). However, a single or two consecutive dose(s) of DNA-MPP did not exacerbate the 
chronic inflammation in the lungs of Scnn1b-Tg mice, as evidenced by the virtually 
identical total cell counts (Figure 4.5D). In addition, H&E staining of lung tissues from 
different treatment groups further confirmed the in vivo safety of DNA-MPP in the 
inflamed lungs (Figure 4.5E-H).  
4.3.4. In vivo ENaC modulation mediated by DNA-MPP  
We next investigated whether DNA-MPP were capable of delivering therapeutic 
plasmids and exerting meaningful therapeutic intervention in the lungs of Scnn1b-Tg 
mice. Specifically, we treated mice with DNA-MPP carrying plasmids encoding shRNA 
against α-subunit of ENaC (shENaC-MPP). While the diseased phenotypes observed in 
the lungs of the Scnn1b-Tg mice are driven by overexpression of β-subunit of ENaC 
[472], we opted to target the α-subunit due to its essential role on the physiological ENaC 
functions [498-500]. We also note that α-subunit is currently serving as a primary clinical 
target for ENaC-based CF therapy [501, 502]. Western blot analysis revealed that a single 
dose of shENaC-MPP was capable of mediating significant downregulation of both 
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glycosylated and non-glycosylated forms of ENaC (Figure 4.6A-B). As expected from 
the earlier reporter multi-dose study (Figure 4.5C), we also confirmed that two 
consecutive doses of shENaC-MPP further reduced the ENaC expression (Figure 4.7). 
Quantitatively, a single and two dose(s) resulted in 30% and 60% ENaC downregulation, 
respectively, compared to the vehicle-treated control mice (Figure 4.6C). To examine 
whether the shENaC-MPP-mediated ENaC downregulation ameliorated the muco-
obstruction in the lungs of Scnn1b-Tg mice, we collected BAL fluid and quantified the 
amount of mucin in the mucus plug. We found that approximately 45% and 60% of 
mucin content were reduced compared to the vehicle-treated control when shENaC-MPP 
were administered once and twice, respectively (Figure 4.6D). In parallel, we conducted a 
control experiment in which we confirmed that the mucin concentration in the lungs of 
Scnn1b-Tg mice remained unchanged when mice received DNA-MPP carrying GFP-
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Figure 4.6. Clinically-relevant effectiveness of DNA-MPP carrying shENaC-encoding plasmids 
(shENaC-MPP) in the lungs of Scnn1b-Tg mice. Western blot (A) imaging and (B) quantitative 
analysis demonstrating downregulation of ENaC in Scnn1b-Tg lungs by a single intratracheal 
dose of shENaC-MPP. G: glycosylated; NG: non-glycosylated. (C) Further downregulation of 
ENaC after repeated doses of shENaC-MPP. (D) Relative total mucin concentration in BAL 
fluids from untreated Scnn1b-Tg mice vs. Scnn1b-Tg mice received a single or two dose(s) of 
shENaC-MPP. Ab-PAS staining of Scnn1b-Tg mouse lungs treated with (E) vehicle (i.e. 
ultrapure water) or (F) 7% HS. Scale bar = 500 μm (G) Enhancement of DNA-MPP-mediated 
overall transgene expression in the lungs of Scnn1b-Tg mice with 7% HS pre-treatment (1 μl/g 
body weight, 3 x/day, 7 days). Inset: treatment regimen (Black arrows: 7% HS pre-treatment; 
Red arrow: DNA-MPP administration). (H) Relative total mucin concentration and (I) total 
number of cells in BAL fluids collected from Scnn1b-Tg mice received single dose of shENaC-
MPP, 7% HS, or sequential treatments of 7% HS and shENaC-MPP in comparison to untreated 
Scnn1b-Tg mouse control. Data represent mean ± S.E.M. Statistically significant as indicated (*p 




4.3.5. Impact of hypertonic saline pre-treatment in vivo 
Hypertonic saline (HS; 7% NaCl) is routinely used in clinic to improve 
pulmonary functions of CF patients by facilitating mucus removal from the lung via 
physiological mucociliary clearance mechanism [503]. We thus hypothesized that pre-
treatments with HS would improve gene transfer efficacy of DNA-MPP due to the 
reduction in mucus burden. Consistent with a prior observation [504], a week regimen of 
intranasal HS (three times a day; 1μl/g of body weight) was highly efficient in removing 
mucus plugs in the lungs of Scnn1b-Tg mice (Figure 4.6E). We then confirmed that the 
HS pre-treatments further enhanced DNA-MPP-mediated transgene expression (i.e. 
luciferase activity) by over an order of magnitude (Figure 4.6G). Encouraged by this 
result, we investigated the combined therapeutic effects of HS pre-treatments followed by 
Figure 4.7. Western blotting demonstrating downregulation of ENaC in the lungs of Scnn1b-Tg 
mice by repeated intratracheal administration of shENaC-MPP. G: glycosylated; NG: non-
glycosylated. 
Figure 4.8. Quantification of O-linked mucin in the lungs of Scnn1b-Tg mice that were untreated, 
vehicle treated, and GFP-MPP treated. 
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a single dose of shENaC-MPP on key pathology in the lungs of Scnn1b-Tg mice, 
including muco-obstruction and inflammation. A modest reduction in the mucin 
concentration was observed in the lungs of Scnn1b-Tg mice received a single dose of 
shENaC-MPP. However, a week regimen of intranasal HS was more effective in 
alleviating the mucus burden and subsequent treatment with shENaC-MPP did not lead to 
further reduction in the mucin concentration (Figure 4.6H). We note that unlike the 
earlier study (Figure 4.6D), we quantified the mucin concentration in the whole BAL 
fluid rather than in mucus plugs due to their absence in the lungs of HS-treated mice. 
Interestingly, the total cell count in BAL fluid was significantly reduced in the lungs of 
mice that received sequential HS pre-treatments and shENaC-MPP, whereas either 
treatment alone failed to do so (Figure 4.6I).  
4.3.6. Apical transfection of well-differentiated primary CF HBE grown on ALI 
To evaluate the relevance of DNA-MPP to human muco-obstructive lung airways, 
we next established ALI cultures with human primary CF bronchial epithelial cells 
harvested from an F508del homozygous CF patient. After the tightly sealed monolayer 
and continuous mucus secretion were confirmed, we treated the ALI cultures apically 
with either DNA-CP or DNA-MPP carrying GFP-encoding plasmids. Of note, each well 
received a very small volume (0.1 mg/ml plasmids in 8 μl) to minimize dilution of the 
apical mucus gel layer [505]. Confocal microscopy revealed that while the transgene 
expression mediated by DNA-CP was negligible (Figure 4.9A), relatively widespread 
GFP signal was observed in the well that received DNA-MPP (Figure 4.9B). 
Quantitatively, DNA-MPP provided marked greater level (i.e. GFP intensity; Figure 
4.9C) and coverage (Figure 4.9D) of transgene expression compared to DNA-CP. 
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4.3.7. Ex vivo and in vivo characterization of other PBAE-based MPP formulations 
As an exploration, we engineered a library of eight DNA-MPP formulations, 
including the DNA-MPP formulation used in this study, that share the same PEG-
conjugated PBAE but different PBAE, in order to elucidate the impact of subtle chemical 
modifications to colloidal stability, diffusivity in mucus, and gene transfer efficiency. We 
found that all eight MPP formulations, albeit presence of slight variation, exhibited 
virtually identical hydrodynamic diameter, ζ-potential, and polydispersity index (PDI) 
(Table 4.2). However, when their colloidal stability was tested in BALF over the period 
of four hours, some formulations were more stable than others (Figure 4.10). We next 
evaluated their ex vivo mucus-penetrability and in vivo gene transfer efficiency. Due to 
technical feasibility and the finite resource of CF sputum and Scnn1b-Tg mice, we 




Figure 4.7 In vitro transgene expression in ALI cultures of primary CF HBE cells. 
Representative confocal images of GFP transgene expression mediated by (A) DNA-CP or (B) 
DNA-MPP. Scale bar = 100μm. Image-based quantification of (C) level and (D) coverage of 
GFP transgene expression mediated by DNA-CP versus DNA-MPP. Data represent mean ± S.D. 
Differences are statistically significant as indicated (*p < 0.05; Student’s t-test). 
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stability in BALF. Interestingly, we did not find any statistically significant difference in 


































































































We here demonstrate that a synthetic gene delivery platform uniquely designed to 
efficiently penetrate the airway mucus gel layer (i.e. DNA-MPP) provides widespread 
reporter transgene expression throughout the lungs of transgenic mice emulating muco-
obstructive lung diseases (i.e. Scnn1b-Tg). Our image-based blinded analysis revealed 
that DNA-MPP provided at least 30% airway coverage of transgene expression on 
average in the lungs of Scnn1b-Tg mice and ALI cultures of primary human CF bronchial 
epithelium. In contrast, an otherwise identical mucus-impermeable formulation (i.e. 
DNA-CP) exhibited less than 10% coverages in these highly relevant CF airway models. 
Encouragingly, it has been demonstrated using an in vitro model of human primary CF 
ciliated airway epithelium that functional CFTR protein production in 25% of cells 
restore normal mucus transport rates [37]. We acknowledge that a next step in the line of 
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Figure 4.9. Ex vivo and in vivo validation of four MPP formulations. (A) Dot plot of median 
of MSD of DNA-MPPs at a timescale of 1 s in individual human CF sputum samples. (B) 
Overall level of in vivo transgene expression mediated by single administration of various 





this study would be confirmation of the findings using a more quantitative method, such 
as flow cytometry. 
While the widespread coverage resulted in a high-level transgene expression, 
DNA-MPP exhibited about an order of magnitude or more lower levels in the lungs of 
Scnn1b-Tg mice compared to an AAV serotype that we previously confirmed for 
efficient mucus penetration (i.e. AAV6; [505]). However, we found in this study that two 
doses of DNA-MPP markedly enhanced the level of transgene expression compared to a 
single administration, underscoring that our formulation did not elicit therapy-
inactivating immunogenicity inevitably observed for virus-based gene vectors [506]. To 
this end, DNA-MPP may provide transgene expression levels on par or greater than 
mucus-penetrating viral vectors by multiple doses. In a previous study, we established a 
library of DNA-MPP formulations consisting of various core polymer structures but 
sharing the same PEG-conjugated polymer [488]. Through our well-established ex vivo 
multiple particle tracking in CF sputum [206] and in vivo transfection of Scnn1b-Tg 
lungs, we found that four distinct DNA-MPP formulations exhibit similar degree of 
efficient penetration of CF sputum as well as robust transgene expression (Figure 4.11), 
presumably due to the same PEGylated surface in all four MPP formulations. Flow 
cytometric analysis or DNA barcode method [507] to elucidate specific cell types 
transfected by the four formulations may reveal differences in cell tropism and provide 
versatile strategies for treatment of muco-obstructive lung diseases.  
We have previously shown the DNA-MPP does not trigger an acute inflammatory 
response in the lungs of healthy mice [488], but it is critical to retain the safety in 
diseased lungs. We thus demonstrate here that DNA-MPP does not exacerbate chronic 
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inflammation readily established in the CF/COPD-like lungs of Scnn1b-Tg mice. This 
finding suggests that DNA-MPP would be safe even in the immunologically vulnerable 
lung environment inherent to muco-obstructive lung diseases.  
We discovered that a single dose of DNA-MPP carrying plasmids encoding 
shRNA against ENaC (i.e. shENaC-MPP) markedly reduced the level of ENaC protein 
production in the lungs of Scnn1b-Tg mice, and the effect was further pronounced when 
an additional dose was given. Importantly, the mucus burden was significantly reduced 
by the shENaC-MPP-mediated downregulation of ENaC presumably due to airway 
rehydration followed by partial restoration of MCC. In support of the scenario, it has 
been recently reported that three times daily intranasal administration of ENaC-inhibitory 
peptides significantly increases the ASL height (i.e. airway rehydration) in the airways of 
neonatal Scnn1b-Tg mice [508]. Likewise, ENaC antagonists have been shown to restore 
and/or increase the ASL height in ALI cultures of human CF bronchial epithelial cells 
[508, 509]. Of note, Zhou et al. demonstrated that a small molecule-based ENaC 
inhibitor, amiloride, given at an identical dosing schedule applied to the aforementioned 
peptides prevented mucus obstruction in the airways of neonatal Scnn1b-Tg mice, but 
therapeutic reversion was not achieved with adult mice [493]. In contrast, we report here 
a moderate but significant mitigation of mucus plugging in the lungs of Scnn1b-Tg mice 
treated with shENaC-MPP at the ages of 4 weeks when muco-obstructive phenotype is 
fully established [472, 496]. 
We report that pre-treatment with HS markedly increases the overall level of 
transgene expression mediated by the subsequently administered DNA-MPP. Of note, an 
appreciable amount of DNA-MPP, despite the excellent mucus-penetrating ability [488], 
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was found within the mucus plugs in the airways of Scnn1b-Tg mice that did not receive 
the pre-treatment. Thus, the further enhancement of transgene expression is most likely 
attributed to the significant reduction of the particle-trapping mucus plugs via the pre-
treatment as evidenced by our histological analysis and a prior report [504]. We found 
that the airway-rehydrating HS alone failed to ameliorate chronic inflammation inherent 
to the model, in agreement with prior observations with both Scnn1b-Tg mice [504] and 
CF patients [503]. Further, even a remarkable ENaC downregulation achieved by 
shENaC-MPP was insufficient in altering the inflammatory profile. However, a 
combinatory regimen of HS and shENaC-MPP roughly halved the inflammatory burden 
in the lungs of Scnn1b-Tg mice. The findings here suggest that a threshold of ENaC 
downregulation required for airway rehydration relevant to intervening the chronic 
inflammation may exist at least in this model. Of note, a synergistic effect of HS and 
ENaC inhibition on airway rehydration, but not chronic inflammation, has been 
previously reported using a preclinical model [510].  
Success of gene therapy for muco-obstructive lung diseases such as CF has been 
ever-elusive. Excellent pre-clinical results from numerous viral and non-viral gene 
vectors have not translated well to the clinics. As mentioned earlier, the disconnect 
between pre-clinical and clinical studies may be attributed to the lack of animal models 
that accurately depict the pathobiology. Consequently, the gold standard for testing the 
effectiveness of a gene vector for muco-obstructive lung diseases has been the use of 
primary CF HBE grown at ALI, where a gene vector may experience pathological 
barriers such as mucus, ciliated cells, tight epithelial junctions, and other intracellular 
barriers. There has been reports of in vitro non-viral gene transfer on non-differentiated 
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airway epithelial cells [511, 512] or normal HBE [513, 514] grown on ALI, or with the 
use of active gene transfer techniques such as electroporation [515] to address the muco-
obstructive lung disease phenotypes exhibited in vitro. While these studies met their 
respective endpoints and have added great value to the field, the barriers to gene therapy 
of muco-obstructive lung diseases were either bypassed or not adequately addressed. 
Similarly, in vitro studies of viral gene vectors have been conducted on primary cells 
grown at ALI with apical mucin concentration that is lower than naturally or 
pathologically secreted airway mucus, or with a large volume of viruses that may dilute 
and alter the barrier properties of apically secreted mucus [109, 112, 481, 482, 505]. It 
should be noted that careful recapitulation of biological barriers in both in vitro and in 
vivo settings should be considered in order to assess the clinical applicability and 
relevance of gene transfer agents. Importantly, we found here that apically administered 
DNA-MPP is capable of mediating widespread transgene expression in mucus-covered 
ALI cultures of primary CF HBE cells compared to DNA-CP, which is consistent with 
our observations from in vivo studies with the Scnn1b-Tg mouse model. From our pilot 
study of delivering GFP-encoding plasmid via DNA-MPP, we learned that DNA-MPP is 
capable of apically transfecting fully differentiated primary CF HBE, an unprecedented 
result in the field of non-viral DNA delivery. Currently we are under optimization 
process in order to deliver a therapeutic gene (i.e. CFTR, shENaC). Moreover, delivery of 
other nucleic acid (i.e. mRNA, miRNA) as well as gene-editing components (i.e. 





In this study, we engineered a novel synthetic gene carrier platform capable of 
penetrating the human CF sputum barrier as well as the mucus barrier in the lungs of a 
mouse model of muco-obstructive lung diseases. We found that DNA-MPP, compared to 
mucus-impenetrable DNA-CP, achieves more widespread and uniform distribution in 
muco-obstructed mouse lungs, and provides higher transgene expression. We found that 
DNA-MPP is capable of delivering therapeutically relevant gene to this mouse model and 
assert phenotypic change. we also show that this effect is amplified when the mice are 
pre-treated with hypertonic saline, a common adjuvant given in the clinic. Lastly, we 
show that DNA-MPP is capable of apically transfecting mucus-covered primary 
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